Phosphatidylserine clustering by the Ebola virus matrix protein is a critical step in viral budding

Monica L Husby1,2, Souad Amiar1,2†, Laura I Prugar3‡, Emily A David1,4†, Caroline B Plescia1,‡, Kathleen E Huie3‡, Jennifer M Brannan3, John M Dye3‡, Elsje Pienaar2,4, Robert V Stahelin1,2,*†

Abstract

Phosphatidylserine (PS) is a critical lipid factor in the assembly and spread of numerous lipid-enveloped viruses. Here, we describe the ability of the Ebola virus (EBOV) matrix protein eVP40 to induce clustering of PS and promote viral budding in vitro, as well as the ability of an FDA-approved drug, fendiline, to reduce PS clustering and subsequent virus budding and entry. To gain mechanistic insight into fendiline inhibition of EBOV replication, multiple in vitro assays were run including imaging, viral budding and viral entry assays. Fendiline lowers PS content in mammalian cells and PS in the plasma membrane, where the ability of VP40 to form new virus particles is greatly lower. Further, particles that form from fendiline-treated cells have altered particle morphology and cannot significantly infect/enter cells. These complementary studies reveal the mechanism by which EBOV matrix protein clusters PS to enhance viral assembly, budding, and spread from the host cell while also laying the groundwork for fundamental drug targeting strategies.

Keywords Ebola virus; matrix protein; phosphatidylserine; plasma membrane; viral budding

Introduction

Ebola virus (EBOV), which was first discovered in 1976, has been of much concern since the unprecedented 2014–16 outbreak in Western Africa (Bremen et al., 2016). These fears were exacerbated with the 2018–2020 EBOV outbreak in the Democratic Republic of Congo (> 2,200 fatalities) as well as a small outbreak there in 2021. The FDA recently approved an EBOV vaccine and a monoclonal antibody cocktail (Graul et al., 2020; Mullard, 2020); however, the duration and breadth of these outbreaks and that of SARS-CoV-2 underscore the dangers of reoccurring outbreaks and the imminent need to develop small molecule counter measures to treat patients who test positive for EBOV. Further, there is still a large gap in knowledge in how EBOV hijacks host cell components to replicate and spread from cell-to-cell, elucidation of which may identify new drug targets.

In the Filoviridae family, EBOV and Marburg virus (MARV) are lipid-enveloped negative-sense single-stranded RNA viruses (Mühlberger, 2007; Banadyga et al., 2016). One commonly overlooked characteristic of many pathogenic viruses, including EBOV and MARV, is their lipid envelope, which is acquired from the host cell they infect. Furthermore, lipid-enveloped negative-strand RNA viruses possess limited viral machinery, often encoding for just a handful of viral proteins. Among these viral proteins is the multifunctional matrix protein. These matrix proteins, including the VP40 protein of EBOV (eVP40) and MARV (mVP40), are essential to viral assembly and egress (Stahelin, 2014; Madara et al., 2015). In fact, independent expression of eVP40 or mVP40 leads to the production of virus-like particles (VLPs), nearly indistinguishable from infectious virions (Jasenosky et al., 2001; Noda et al., 2002; Licata et al., 2003). Although these matrix proteins travel through different trafficking pathways within cells, they coalesce at the plasma membrane (PM) to form the viral matrix, which directs viral assembly, budding and the acquisition of their characteristic lipid envelope (Panchal et al., 2003; Jasenosky & Kawaoka, 2004; Wang et al., 2010; Bornholdt et al., 2013; Oda et al., 2015; Amiar & Stahelin, 2020; Wan et al., 2020). Importantly, phosphatidylserine (PS) has been implicated in recruiting matrix proteins to the PM and coordinating the assembly of progeny virions (Adu-Gyamfi et al., 2015; Wijesinghe & Stahelin, 2015; Bobone et al., 2017; Del Vecchio et al., 2018).

While lipids play a critical role in assembly of new viral particles, lipids are also actively involved in viral entry in a phenomenon known as “apoptotic mimicry”. Apoptotic mimicry is central to the efficient entry of numerous lipid-enveloped viruses (Jemielity et al., 2013; Möller-Tank et al., 2013; Carnecc et al., 2015). During apoptotic mimicry, PS is transferred from the inner to the outer leaflet of the PM; this causes PS to become a component of the outer viral

1 Department of Medicinal Chemistry & Molecular Pharmacology, Purdue University, West Lafayette, IN, USA
2 Purdue Institute of Inflammation, Immunology and Infectious Disease (PI4ID), Purdue University, West Lafayette, West Lafayette, IN, USA
3 United States Army Medical Research Institute of Infectious Diseases USAMRIID, Fort Detrick, Frederick, MD, USA
4 Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN, USA
*Corresponding author. Tel: +1 7654941152; E-mail: rstaheli@purdue.edu
†These authors contributed equally to this work
‡These authors contributed equally to this work
envelope during infection (Nanbo et al., 2010; Adu-Gyamfi et al., 2015; Amara & Mercer, 2015). Subsequently, the exposed PS in the viral envelope is recognized by target cell receptors for viral uptake, continuing the viral lifecycle (Kondratowicz et al., 2011; Möller-Tank et al., 2013; Brunton et al., 2019).

The two bilayers of the PM have varying compositions of four main phospholipid classes asymmetrically distributed across the two bilayers (Bell et al., 1981; Van Meer et al., 2008). However, the most abundant anionic lipid within the inner leaflet of the PM is PS, a frequent participant in peripheral protein recruitment (Cho & Stahelin, 2005; Stahelin et al., 2014; Kerr et al., 2018). Extensive work has looked at the dynamic nature of lipids within the PM, including PS, and their tendency to cluster into domains several hundred nanometers in size (Fairn et al., 2011; Bobone et al., 2017; Hirama et al., 2017). Clustering of anionic lipids into domains enriches regions of the PM with anionic charge, creating a platform for electrostatic interactions at the PM and cytosolic interface for peripheral protein recruitment. This phenomenon has been reported between PS and the matrix protein of influenza A virus (Bobone et al., 2017). Although significant work has underscored the importance of PS in filovirus budding and entry (Möller-Tank et al., 2013; Möller-Tank & Maury, 2014; Soni & Stahelin, 2014; Stahelin, 2014; Adu-Gyamfi et al., 2015; Del Vecchio et al., 2018; Brunton et al., 2019), the molecular details of the interaction has not been explored in the context of the lateral organization of PS, matrix assembly or implications on viral spread.

The FDA-approved drug, fendiline, has been reported to reduce PS levels within the PM inner leaflet (Cho et al., 2015; van der Hoeven et al., 2018), which was sufficient to inhibit the oncogenic protein K-Ras PM localization and signaling (van der Hoeven et al., 2013, 2018). Fendiline was initially approved by the FDA in the 1970s as a non-selective calcium channel blocker to treat coronary heart disease (Bayer & Mannhold, 1987); however, these recently identified off target properties were found to be calcium independent and associated with the indirect inhibition of acid sphingomyelinase (ASM) (Cho et al., 2015; van der Hoeven et al., 2018). eVP40 and mVP40 have been shown to utilize PS for their PM localization, assembly, and production of progeny virions (Adu-Gyamfi et al., 2015; Wijesinghe & Stahelin, 2015; Del Vecchio et al., 2018; Johnson et al., 2021); however, detailed molecular insight into this relationship is lacking. To delineate the molecular architecture and requirements of PS concentration on VP40 assembly, oligomerization and budding, we employed biochemical and biophysical assays in vitro and in cells. We also tested the ability of the mechanism by which VP40 clusters PS in vitro and in cells. We hypothesized that reduction of PS from the PM with fendiline treatment would perturb filovirus assembly and inhibit viral budding. Lastly, fendiline treatment was tested as a potential therapy for inhibition of EBOV budding and spread in biosafety level (BSL)-2 and BSL-4 models of infection.

**Results**

**EBOV VP40 localizes to PS-enriched regions in synthetic membranes and in living cells**

eVP40 has been reported to have selectivity and high affinity for PS (Ruígrok et al., 2000; Scianimanico et al., 2000; Adu-Gyamfi et al., 2015; Del Vecchio et al., 2018) and PI(4,5)P₂ (Johnson et al., 2016; preprint: Johnson et al., 2018), both in vitro and in cells. To establish an in vitro system for eVP40-PS colocalization, we employed a giant unilamellar vesicle (GUV) system with fluorescently labeled His₆-eVP40 and a fluorescent PS molecule, TopFluo® TMR-PS (tetramethylrhodamine-PS (TMR-PS)). Dipalmitoylphosphatidylserine (DPPS) was chosen for this assay as eVP40 associates with saturated PS containing membranes in vitro more significantly than PS mono- or diunsaturated containing membranes. In GUVs supplemented with 40% DPPS, a homogeneous ring structure of eVP40-Alexa488 surrounding the GUV membrane (Fig EV1A, middle panel) was observed and a random plot profile analysis indicated a small overlap of the two fluorescence signals at the membrane (Fig EV1C, indicated by the asterisk). To investigate further the ability of eVP40-Alexa488 to associate with membranes similar to the PM, GUVs containing both 40% DPPS and 2.5% PI(4,5)P₂ were used (Fig EV1A right panel; See Materials and Methods section for important temperature preparation guidelines). The plot profile analysis of the image in Fig EV1A revealed a strong overlap between the two fluorescence signals (eVP40 and TMR-PS) (Fig EV1D). The protein enrichment analysis also supported this previous observation with an enrichment index of ~ 5.4 ± 1, four times more than membranes devoid of PI(4,5)P₂ (Fig EV1E). These data are in agreement with the previously published findings that eVP40 requires both PS and PI(4,5)P₂ for efficient membrane binding and oligomerization and suggest eVP40 is able to enrich PS at sites of VP40 oligomerization.

To expand upon our findings, we investigated whether eVP40 localized to PS-enriched regions within the PM of live cells. To visualize PS and protein localization simultaneously, we transiently expressed EGFP-fused proteins in HEK293 cells and supplemented the cells with TMR-PS immediately prior to imaging (Fig EV2A). To test the hypothesis that eVP40 localizes to PS-enriched regions of the PM, we examined the plot profile analysis of TMR-PS and eVP40 by expressing functionally unique EGFP fused proteins: WT-eVP40, Lact-C2 (a PS-binding reporter), K224A-eVP40 (a PS-binding residue mutant; Del Vecchio et al., 2018), and WE/A-eVP40 (oligomerization-deficient mutant; Adu-Gyamfi et al., 2012; Bornholdt et al., 2013). The fluorescence profile of EGFP-WT-eVP40 vs. TMR-PS revealed a strong overlap between the two fluorophores (Fig EV2A and D). These cellular data corroborate our in vitro data, demonstrating that EGFP-eVP40 localizes to PS-enriched regions of both model membranes and in the PM of cells. Additionally, there was no significant fluorescence signal overlap between the EGFP-K224A-eVP40 mutant and TMR-PS (Fig EV2A and E), which supports the requirement of PS binding for PM localization of eVP40 (Del Vecchio et al., 2018). Importantly, random plot profile analysis revealed a moderate overlap in the fluorescence signals of the oligomerization-deficient mutant WE/A-eVP40 and TMR-PS (Fig EV2A and F). This is important to note as this protein is still able to interact with PS at the PM, however, is unable to properly oligomerize (Hoenen et al., 2010; Adu-Gyamfi et al., 2012, 2013). These results suggest VP40 interacts with PS at the PM inner leaflet as a dimer without significant oligomerization, in line with VP40 in vitro lipid binding (Del Vecchio et al., 2018).

**EBOV VP40 enhances clustering of PS in synthetic membranes and in living cells**

Biophysical and molecular studies into PS dynamics in model membranes and living cells revealed that PS basally distributes into
clustered domains enriched with PS (Fairn et al., 2011; Bobone et al., 2017; Hiramatsu et al., 2017). Interestingly, cellular proteins such as Annexins are known to significantly enhance the clustering of PS (Menke et al., 2005) and viral proteins such as M1 of Influenza A virus have a selectivity for these PS clusters (Bobone et al., 2017). However, detailed examination of PS clustering and whether filovirus matrix proteins such as eVP40 alter the organization of PS has not yet been explored.

Confocal 3D reconstruction of GUVs (with DPPS and PI(4,5)P2) indicated different structures of TMR-PS clusters observed where eVP40-Alexa488 fluorescence was enriched (Fig EV1A, three right columns). Furthermore, the Mander’s coefficient index of correlation was quantified (between the TMR-PS and eVP40-Alexa488) with varying lipid compositions (Fig 1B) demonstrating a statistically significant increase in PS clustering when eVP40-Alexa488 was incubated with GUVs containing both DPPS and PI(4,5)P2 (Fig 1B; *P < 0.0001). These results suggest that eVP40 induced PS clustering in vitro, which was significantly enhanced in the presence of both PS and PI(4,5)P2, akin to the lipid composition typically found in the PM inner leaflet.

Next, we were interested to determine whether eVP40 was able to induce PS clustering in synthetic membranes in the absence of PI(4,5)P2. Therefore, we performed a TMR self-quenching experiment as described previously (Zhao et al., 2010; Wen et al., 2018). The TMR fluorescent group has potent self-quenching properties when two molecules or more are brought to close distance from each other. We tested the ability of eVP40 to undergo TMR self-quenching when fluorescent PS was incorporated in lipid vesicles, as a secondary effect to eVP40-induced PS-clustering. We also tested different eVP40 concentrations and different PS ratios to investigate if TMR self-quenching was concentration dependent. The strongest TMR self-quenching in all membranes was observed at 1.5 μM eVP40 (Fig 1C). As expected, higher PS molar ratios resulted in stronger eVP40 induction of TMR self-quenching except for a high molar ratio of DPPS (60% molar ratio). However, the addition of PI(4,5)P2 at 2.5% molar ratio to 60% DPPS-containing membranes rescued TMR self-quenching similarly to 40% DPPS-containing membranes. Further, DPPS-containing membranes at 60% molar ratio with or without PI(4,5)P2 displayed a maximum of TMR-PS self-quenching at 2 μM eVP40. These observations may indicate a saturation of the liposome membranes with eVP40 at high PS concentrations. Altogether, this assay demonstrated that eVP40 is able to cluster PS, which is enhanced in the presence of PI(4,5)P2.

We next examined if eVP40 enhanced PS clustering in the PM of living cells. As previously mentioned, PS selectively localizes into clustered regions (Fairn et al., 2011; Bobone et al., 2017; Hiramatsu et al., 2017); and we were able to detect a basal level of PS-enriched clusters in our control GFP expressing cells, with PS clusters accounting for ~ 8% of the PM (Fig 1D top panel and E). Our method was further validated by expressing an additional control protein with a glycosylphosphatidylinositol membrane anchor conjugated to GFP (GFP-GPI), which revealed PS clusters in ~ 8% of the PM area (Figs 1E and Representative image in EV3B top panel).

We next sought to determine if our technique accurately captured enhanced PS clustering using the established EGFP-Annexin A2 PS reporter (Menke et al., 2005). As shown in Fig 1D–E, expression of EGFP-Annexin A2 significantly enhanced PS clustering roughly 2-fold, compared with EGFP expressing cells (***P = 0.0001). Taken together, these findings corroborate the previously reported effect of Annexin A2 on PS organization (Menke et al., 2005), as well as validate the method developed for our assay. In contrast, expression of EGFP-PLCδ-PI(4,5)P2 or EGFP-LactC2 did not significantly alter the extent of PS clustering (Fig 1E). This confirmed that transient expression of fluorescently conjugated lipid-binding proteins is not sufficient to enhance PS clustering at the PM.

Next, we evaluated the effect of eVP40 expression on PS organization across the PM. EGFP-WT-eVP40 increased PS clustering by ~ 2 fold (*P = 0.004), similar to the PS clustering observed with Annexin A2 (Fig 1D and E). However, expression of the PS-binding deficient mutant EGFP-K224A-eVP40 showed no significant change in PS clustering (Fig 1D and E), supporting the hypothesis that eVP40 must interact with PS to promote its clustering at the PM. Additionally, to investigate if eVP40 matrix oligomerization was important for PS clustering, we expressed EGFP-WEA-eVP40 in HEK293 cells. It is important to note that this mutant still colocalizes with PS at the PM (Fig EV2A and F) albeit to a lesser extent than WT (Adu-Gyamfi et al., 2012). Although the WE/A-eVP40 and PS interaction is maintained in cells, no significant increase in PS clustering was observed (Fig 1D and E). To the best of our knowledge, this is the first account of a filovirus matrix protein modulating the organization of PS within the PM. Moreover, these results demonstrate that both membrane binding and oligomerization of eVP40 is central to eVP40-mediated PS clustering.

Figure 1. Clustering of PS by eVP40 in vitro and in HEK 293 cells. A Representative 3D reconstructed confocal images of immobilized GUVs (DPPC:Cholesterol:DPPS:PI(4,5)P2:TopFluor® TMR-PS (red)). Left panel: GUVs incubated without eVP40-Alexa488. Right three panels: GUVs incubated with 1.25 μM eVP40-Alexa488 (green). Scale bar = 5 μm. B Index of correlation (Mander’s coefficient) between TopFluor® TMR-PS and eVP40-Alexa488 of different GUVs compositions incubated with 1.25 μM eVP40-Alexa488. Values are reported as mean ± s.d. A one-way ANOVA with multiple comparisons was performed; n = 3 for 3 technical replicates *P < 0.0001. C % TopFluor® TMR-PS quenching by eVP40 using GUVs (DPPC:Cholesterol:TopFluor® TMR-PS + increasing mol% of PS), 2.5% PI(4,5)P2 was added to GUVs with 60% PS. Fluorescence spectra were recorded (Ex: 547 nm; Em: 550-600 nm); n = 2 technical replicates. D Representative confocal images of HEK293 cells expressing various GFP-fused proteins (green) and supplemented with TopFluor® TMR-PS (red), scale bar = 10 μm. Yellow arrows indicate high intensity PS fluorescent regions. E %PS with PS clusters area of high intensity fluorescence PS clusters over total PM area from images in panel D. Black bars are control proteins and blue bars are eVP40 proteins. Values are reported as mean ± s.d.; N > 18 cells per biological replicate, n = 3 for 3 biological replicates; A one-way ANOVA was performed with multiple comparisons compared with the control GFP %PS clustering (**P = 0.0007, *P = 0.004). Data information: DPPC, dipalmitoyl-phosphatidylcholine; DPPS, dipalmitoyl-phosphatidylserine; GUVs, giant unilamellar vesicles, PM, plasma membrane; PS: phosphatidylserine.

© 2022 The Authors
EMBO reports 23: e51709 | 2022 3 of 24
Figure 1.
eVP40 membrane binding and oligomerization are dependent on phosphatidylserine content in lipid membranes

Next, we hypothesized eVP40 may require PS clustering for productive interactions at the PM during assembly. Enrichment of PS within regions of the PM would provide additional PS molecules available to recruit eVP40 to platforms of viral budding. To investigate how increasing the amount of PS within membranes dictates eVP40 membrane affinity, surface plasmon resonance (SPR) was performed with His,eVP40 and large unilamellar vesicles (LUVs) with increasing concentrations of PS (POPC matrix with PS added from 1 to 22 mol% PS; Fig 2A–C). eVP40 displayed moderate binding to LUVs with 1% PS, with an apparent affinity of 2.5 μM (Fig 2A). However, increasing the concentration of PS to 11% increased the apparent affinity of eVP40 to 0.65 μM (Fig 2B). eVP40 displayed even stronger affinity to vesicles with 22% PS, with an apparent affinity (Kd) of ~0.18 μM (Fig 2C). These results indicate that by increasing the amount of PS in membranes, the affinity of eVP40 to lipid membranes can be modulated. This finding supports the hypothesis that PS clustering may be a mechanism for the virus to provide the necessary electrostatic contacts needed for matrix assembly during viral production.

Once at the PM, VP40 oligomerizes into the extensive matrix that gives rise to the stability and structure of the virion. Previously, Adu-Gyamfi et al (2015) highlighted the importance of PS in this process, where a cell line deficient in PS synthesis showed a significant reduction in eVP40 oligomerization. Moreover, our confocal clustering data (Fig 1D and E) revealed that eVP40 oligomerization is crucial for modulating PS organization into clustered domains. To investigate how increasing PS concentration alters eVP40 oligomerization, we utilized chemical crosslinking of His,eVP40 which had been incubated with LUVs of increasing PS concentration (Fig 2D and E). Introduction of 15% PS into LUVs led to extensive eVP40 oligomerization beyond dimeric eVP40 compared with when 0% PS LUVs were used (Figs 1E and 2D lane 2). We next tested LUVs containing 30 and 60% PS and found that eVP40 oligomerization was even more significantly detected than when just 15% PS was used (Figs 1E and 2D lane 3 and lane 4, respectively). Compared with LUVs with 0% PS, both 30% PS and 60% led to a significant increase in eVP40 oligomerization (*P = 0.021 and *P = 0.017, respectively). Further, eVP40 oligomerization appeared to saturate when 30% PS was included, as increasing PS content to 60% did not increase eVP40 oligomerization (compared with 30% PS). Taken together, these studies suggest a dynamic relationship between PS clustering and eVP40 affinity and oligomerization as a critical step in eVP40 assembly.

Total cellular and plasma membrane levels of phosphatidylserine are reduced by fendiline treatment

A recent study reported an FDA-approved drug, fendiline, inhibited K-Ras PM localization and signaling (Cho et al, 2015) and reduced PM PS content in MDCK cells (Cho et al, 2015). Therefore, it was our goal to determine whether fendiline could also reduce PS levels in the human cell line HEK293, a cell line commonly used in BSL-2 filovirus studies. The initial finding that fendiline reduced PS levels within the PM (40% reduction, IC50 ~ 3 μM) was conducted in MDCK cells using thin-layer chromatography (Cho et al, 2015), therefore it had not been established if this effect was cell-type specific. To address this, we first established fendiline’s toxicity in HEK293 cells after 24 and 48 h of treatment. No significant toxicity was observed in treatments up to 5 μM fendiline (Fig EV4A). To evaluate the effect of fendiline on PS in HEK293 cells, cells were treated with fendiline for 48 h and lipids were extracted and quantified by liquid chromatography–tandem mass spectrometry (LC–MS/MS). We observed a significant reduction in cellular PS levels compared with DMSO-treated cells, after 48-h treatment with 1 μM fendiline (~18% reduction; *P = 0.012) and 5 μM fendiline (~30% reduction; ***P = 0.0003) (Fig 3A). Fendiline exhibited no selectivity in reducing different PS species, as 5 μM fendiline reduced long chain (C > 38) and saturated PS species nearly equally (Fig EV4B). It is important to note that the effect of fendiline on PS was specific in that fendiline treatment had no significant effect on another anionic phospholipid, phosphatidic acid (Fig EV4C). Therefore, our data support the reported finding that fendiline reduced total cellular levels of PS, and that the effect is not cell dependent.

As PS is an integral anionic component of the PM inner leaflet, we sought to confirm that fendiline treatment also reduced PS levels within the PM in HEK293 cells. PS localization within the PM has been readily studied by expressing EGFP-LactC2 in mammalian cells (Yeung et al, 2008; Kay et al, 2012). Therefore, HEK293 cells expressing EGFP-LactC2 were imaged at 24 h (Fig EV4D) and 48 h (Fig 3B) post-treatment with increasing concentrations of fendiline. Single doses of 500 nM fendiline had no effect on EGFP-LactC2 PM localization at 24 or 48 h post treatment (Figs 3C and EV4E, respectively). However, we found a ~30% reduction in PM EGFP-LactC2 localization after 24 h of treatment for both 1 μM (**P = 0.0003) and 5 μM fendiline (**P = 0.0045; Fig EV4E). However, a single dose of 1 μM fendiline treatment did not significantly affect Lact-C2 PM localization after 48 h of treatment (Fig 3C). Conversely, a single dose of 5 μM fendiline significantly reduced Lact-C2 PM localization even at 48 h post treatment (~30% reduction; **P = 0.0031; Fig 3C), a reduction similar to that observed at 24 h post treatment.

Fendiline has been known to target L-type calcium channels in the T-tubules (invaginations of the PM) of muscle cells thereby inhibiting calcium movement and acting as a vasodilator (Bayer & Mannhold, 1987). However, in a number of non-muscle cell lines, fendiline has been shown to increase calcium levels, including hepatoma cells (Cheng et al, 2001), oral cancer cells (Huang et al, 2009), PC prostate cancer cells (Jan et al, 2001), and canine kidney cells (MDCK) (Jan et al, 2000). Fendiline was also specific in the K-Ras inhibitory affect among a number of L-type calcium channel blockers (van der Hoeven et al, 2013) strongly suggesting the fendiline mechanism of action is directly linked to PS depletion and not changes in calcium. Fendiline was shown to inhibit ASM (Cho et al, 2015) thereby reducing PM sphingomyelin, ceramide, PS and cholesterol. Restoration of ASM activity lead to the relocation of the PS reporter LactC2 to the PM (Cho et al, 2015).

Lastly, studies in HEK293 cells, the major cell line used herein, demonstrated endogenous calcium channel currents could be distinguished from heterologous expression of L-type calcium channels (Berjuwok et al, 1996).
Thus, based on rigor of prior research the most likely hypothesis is that fendiline inhibits ASM to alter sphingomyelin levels, which are necessary to maintain proper PS levels in the PM. Recently, fendiline analogs have been developed with nanomolar potency and have been shown to displace ASM, which is membrane bound in acidic lysosomes leading to ASM degradation (Wang et al., 2021).

While the direct mechanism of PS depletion in the PM is not fully understood, transbilayer communication may take place across the plasma membrane between sphingomyelin levels on the outer leaflet and PS on the inner leaflet (Llorente et al., 2013; Skotland & Sandvig, 2019).

**Figure 2.** Effect of PS concentration on eVP40-binding affinity to and oligomerization on membranes.

A–C SPR demonstrates that eVP40 affinity to LUVs increases in relation to PS concentration. (A) Representative normalized sensorgram of His6-eVP40 binding to LUVs containing 1% PS indicating an apparent affinity of 2.5 μM. (B) Representative normalized sensorgram of His6-eVP40 binding to LUVs containing 11% PS indicating an apparent affinity of 0.65 μM. (C) Representative normalized sensorgram of His6-eVP40 binding to LUVs containing 22% PS indicating an apparent affinity of 0.18 μM.

D, E PS concentration in LUVs enhances the ability of His6-eVP40 to oligomerize on membranes. (D) Representative western blot of chemical crosslinking performed on His6-WT-eVP40 following incubation with LUVs of varying PS content (detected by Mouse α-His antibody & HRP-Sheep α-Mouse). (E) Oligomerization capacity was determined from the western blot band density ratio of oligomers/(monomer + dimer) from chemical crosslinking experiments. A one-way ANOVA was performed with multiple comparisons compared with the control 0% PS LUVs control (30% PS *P = 0.02; 60% PS *P = 0.017). n = 3 biological replicates. Values are reported as mean ± s.d.

Data information: SPR: surface plasmon resonance; LUVs: large unilamellar vesicles; PS: phosphatidylserine; HRP: horseradish peroxidase.

**Fendiline reduces PS clustering**

Next, we hypothesized that reduced levels of PS within the PM would therefore reduce the degree of PS clustering. To determine whether fendiline treatment reduced the degree of PS clustering, we utilized the Number & Brightness technique [N&B]. N&B is a quantitative fluorescence microscopy technique that allows one to detect the aggregation state of proteins with pixel resolution in real time (Digman et al., 2008). Previously, N&B was used to quantify PS clustering by analyzing the N&B profile of EGFP-LactC2 (Bobone et al., 2017). To accurately capture PS clustering at the
Figure 3.
Fendiline significantly inhibits authentic EBOV replication

To determine whether the FDA-approved drug fendiline was able to inhibit authentic filovirus replication and spread, we first established the toxicity of fendiline in Vero E6 cells (Fig EV5A) an established model for BSL-4 filovirus studies (Moe et al., 1981), and then monitored the efficacy of fendiline in inhibiting EBOV replication in a BSL-4 setting. Vero E6 cells were used to examine EBOV replication 48-, 72-, and 96-h post-infection at different multiplicity of infection (MOI) with EBOV (Kikwit) (Fig 4A). Following infection, plates were separated into three post-infection treatment groups (day 0, every day dosing (e.d.), or every other day dosing (e.o.d.)).

Fendiline was most effective at reducing EBOV infection in vitro at 20 μM concentrations in each treatment group with statistically significant inhibition observed at each time point and each treatment group (excluding EBOV 48 h, e.d.) (****P < 0.0001, **P < 0.0066) (Fig 4B–D). Percent inhibition was directly affected by timing of treatments following infection. Furthermore, EBOV treatment with fendiline e.d. had the highest inhibition on viral spread at each time point for 20 μM fendiline treatments. Cells of the e.o.d. treatments group, which did not receive treatment immediately following infection with virus, had a dramatically reduced degree of inhibition as compared with the day 0 and e.d. treatment groups, both of which received fendiline immediately following viral infection of 1 h.

Fendiline reduced EBOV-VP40 but not MARV-VP40 localization to the plasma membrane

As both EBOV and MARV-VP40 assembly at the PM is in part governed by PS, we first analyzed both EGFP-eVP40 and EGFP-mVP40 PM localization in cells treated with fendiline for 24 or 48 h. Treatment with 1 and 5 μM fendiline had no significant effect on eVP40 PM at 24 h post treatment (Fig EV5B and C); therefore, EGFP-mVP40 PM localization was not assessed at 24 h. Surprisingly, no significant change in EGFP-mVP40 PM localization was observed after 48 h with either 1 μM or 5 μM fendiline treatment (Fig 5A bottom panel and B); therefore, mVP40 was excluded from further experiments. In agreement with our results thus far, 1 μM fendiline did not significantly inhibit EGFP-eVP40 PM localization after 48 h.
of treatment (Fig 5A top panel and C). However, treatment with 5 μM fendiline for 48 h led to a modest reduction in EGFP-eVP40 PM localization (~6% reduction compared with control-treated cells; not significant as P = 0.08) (Fig 5A top panel and C). However, the reduction of eVP40 PM localization was not robust enough to lead to the observed inhibition of EBOV by fendiline treatment in our BSL-4 studies (Fig 4B–D). One possible explanation is that a limitation of this technique is the inability to differentiate the extent of VP40 oligomerization occurring using basic confocal microscopy. Therefore, it is possible that fendiline reduced PS levels within the PM, but not significantly enough to block VP40's ability to bind to the PM.

**VP40 oligomerization is significantly reduced by fendiline treatment**

PS is also a key factor promoting the self-assembly of VP40 into the matrix layer of the budding virion (Adu-Gyamfi et al., 2013, 2015). This self-assembly process has been highlighted in our in vitro crosslinking data (Fig 2D and E) as well as previously reported in live cells utilizing the N&B technique (Adu-Gyamfi et al., 2012). To assess how fendiline impacted eVP40 oligomerization in cells, we examined the oligomerization profile of EGFP-eVP40 using the previously described N&B (Adu-Gyamfi et al., 2012, 2015; Johnson et al., 2016) (Fig 5D and E). The crystal structure, biochemical analysis, and recent Cryo-ET of eVP40 at the PM strongly suggests eVP40 binds to the PM as a dimer (Bornholdt et al., 2013; Del Vecchio et al., 2018; Wan et al., 2020). eVP40 dimers subsequently oligomerize into larger oligomers via CTD-CTD interactions between dimers, leading to the eVP40 matrix layer formation (Wan et al., 2020). Therefore, for our data to coincide with the current models of eVP40 oligomerization, EGFP-eVP40 oligomers were grouped into bins based on multiples of the dimer. Since analyzing eVP40 oligomerization by an increase in every dimer leads to an abundance of data as well as partial overlap in fluorescence signal for each dimer addition, we simplified the data presentation and analysis to different bins of eVP40 oligomers (i.e. dimer-hexamer, hexamer-12mer, 12mer–18mer, and > 18mer). The average percentage of pixels in each bin was calculated and plotted for HEK293 cells expressing EGFP-eVP40 and treated with either the control or indicated concentration of fendiline for 48 h (Fig 5D and E).
Figure 5.
Large eVP40 oligomeric structures corresponding to each bin size were readily detectable at the PM in control-treated cells (Fig 5 D top panel and E), with ~72% of eVP40 found as a dimer-hexamer, ~16% as a hexamer-12mer, ~8% as a 12mer–18mer, and 3% in complexes > 18mer. Treatment with 1 μM fendiline led to a ~8% increase in dimeric-hexameric eVP40, and small decreases in the larger oligomeric structures, although no changes were statistically significant (Fig 5D middle panel and E). However, the oligomeric profile of eVP40 was statistically different when cells were treated with 5 μM fendiline. Following 5 μM fendiline treatment, there was a significant increase in eVP40 found in the dimer-hexameric state (~13% increase; **P = 0.0035) which was counterbalanced by an equal reduction in the larger oligomeric states (~6% reduction for hexamer-12mer, 5% reduction for 12mer–18mer, and ~3% reduction for eVP40 structures > 18mer) (Fig 5D bottom panel and E). These results support our hypothesis that by reducing PS concentration and therefore the pool of PS available for clustering, eVP40 is unable to properly oligomerize once it traffics and binds to the PM. This, in combination with the modest reduction in eVP40 PM binding following fendiline treatment, may therefore impact the production of viral particles as suggested from our BSL-4 studies.

Fendiline reduced VLP production at the plasma membrane

As fendiline reduced VP40 oligomerization, we sought to determine the effect of fendiline treatment on VLP production using functional budding assays. No significant effect on VLP production was observed for cells treated with 0.5 or 1 μM fendiline at either 24 h (Fig 6A lane 3,4 and B) or 48 h post-treatment (Fig 6C lanes 3,4 and D). However, treatment with one dose of 5 μM fendiline for 24 h led to a ~25% reduction in VLP production (Fig 6A lane 5 and B) compared with DMSO-treated cells (Fig 6A lane 2 and B). More importantly, this reduction in VLP production was even more robust when monitored at 48 h post-treatment, with a statistically significant ~60% reduction in the relative budding efficiency of 5 μM fendiline-treated cells (*P = 0.0260) (Fig 6C lane 5 and D). The reduction in VLPs is supported by our previous findings that a single dose of 5 μM fendiline reduced PS levels, PS clustering and the extent of eVP40 oligomerization at the PM. Therefore, we hypothesize that reduced virus budding is at least partially responsible for fendiline efficacy in authentic EBOV studies (Fig 4).

To further investigate the reduction of VLP production in fendiline-treated cells, and to determine if there were any observable morphological changes in VLPs, scanning electron microscopy
(SEM) experiments were performed (Fig 6E and F). Micrographs of cells expressing FLAG-eVP40 and treated with 5 μM fendiline revealed minimal VLP production at the PM compared with control-treated cells (Fig 6F). These findings support the hypothesis that fendiline treatment considerably reduces the production of EBOV VLPs.

VLP morphology is altered by fendiline treatment

The structure and stability of filoviruses is derived from the VP40 matrix underlying the lipid envelope of virions. Therefore, we utilized transmission electron microscopy (TEM) of purified VLPs to determine if disturbing matrix assembly and altering the lipid
components of the PM with fendiline treatment changed VLP morphology and possibly infectivity (Fig 7A–C). During filoviral entry, surface exposed GP and viral envelope PS interact with the receptor T-cell immunoglobulin receptor-1 (TIM-1) (Moller-Tank et al, 2013; Brunton et al, 2019). To recapitulate entry-competent VLPs (eVLPs), we co-expressed eVP40 with the EBOV glycoprotein (eGP). We performed TEM of eVLPs purified from control and 5 μM fendiline-treated cells and used ImageJ software to analyze VLP length and diameter (Fig 7A–C). Control eVLPs were homogenous in length with a mean length of 4.1 μm ± 2.9 (Fig 7A left panel and B). Control eVLP diameter also exhibited a level of heterogeneity but had a consistent diameter of 75 nm ± 12.9, which is similar to previous studies of both virions and VLPs (Noda et al, 2002; Liu, 2014) (Fig 7A left panel and C). The length and diameter of eVLPs derived from 5 μM fendiline-treated cells were significantly less than control eVLPs. Strikingly, fendiline treatment reduced VLP length by ~ 35%, from 4.1 μm to 2.7 μm (*P = 0.0139) (Fig 7A right panel and B) and modestly reduced eVLP diameter (*P = 0.043) (Fig 7A right panel and C). To ensure that eVLPs derived from fendiline-treated cells were not more susceptible to damage during the purification, circular dichroism thermal melting was performed and no difference in eVLP stability was observed (Appendix Fig S1). Reduced eVLP length and diameter could translate into reduced infectivity (e.g., less PS and less surface area and membrane available to bind TIM-1), therefore we next sought to determine the effect of fendiline on eVLP entry.

Fendiline blocks EBOV eVLP entry

A common characteristic of viral infectivity is the relationship between virion-associated PS and the TIM-1 receptor on target cells (Kondratowicz et al, 2011; Moller-Tank et al, 2013; Wang et al, 2017; Dejarnac et al, 2018; Brunton et al, 2019). Moreover, it has been previously reported that other ASM inhibitors blocked EBOV infectivity (Miller et al, 2012). To determine whether fendiline treatment reduced the entry of eVLPs, we performed a fluorescent-based entry assay using 1,1’-diocadecyl-3,3,3’,3’-tetramethylindocarbocyanine perchlorate (DiI) labeled eVLPs (Nanbo et al, 2010; Kuroda et al, 2015; Nanbo & Kawaoaka, 2019). By testing entry of eVLPs derived from fendiline-treated cells rather than the entry of eVLPs on fendiline-treated cells, we were able to determine how fendiline treatment affected eVLP entry rather than how inhibition of ASM in target cells affected eVLP entry (as previously described Miller et al, 2012). If entry of the eVLPs was not altered by fendiline treatment, one would expect a dose-dependent increase in infectivity with increasing TIM-1 expression. Conversely, if eVLP entry was inhibited by fendiline treatment, a dose-dependent increase in eVLP entry would not be observed with increasing TIM-1 expression.

TIM-1 overexpression was increased in target cells and a detectable and significant dose-dependent increase in control eVLP entry was observed, by > 200% in the highest TIM-1 overexpressing cells (compared with no TIM-1 overexpression; Fig 7D top panel and E). Remarkably, no measurable increase in eVLP entry was observed for fendiline-derived VLPs across any of the TIM-1 overexpressing target cell conditions (Fig 7D bottom panel and E). From this comparison, these results suggest that the impaired entry of fendiline eVLPs is a result of reduced PS in the viral envelope, either from smaller VLPs or a lower % of PS content. These findings in combination with the observed reduction in VLP formation further substantiate the significance of reduced EBOV infection observed in our live virus studies following fendiline treatment.

Mathematical model of in vitro experiments

We next used a mathematical model to predict how the effects of fendiline on both viral budding and entry combine to produce the observed effects in the BSL-4 assays. We calibrated our mathematical model (equations 1−3) to experimental data from the budding and entry assays using approaches and parameter settings outlined in the methods and Appendix Table S1. Results from our two-phase calibration procedure are shown in Fig 8A–F and Appendix Fig S2. The model captures key features of the data including a progressive increase in percentage of infected cells over time, differences between MOI and limited cell death in the first 48 h of the experiment (Appendix Fig S2).

The dynamics behind these calibrated figures suggested that fendiline treatment significantly delayed the infection process (Fig 8 G and H), resulting in the observed decrease in percent infected cells with treatment over 4 days. The effects of fendiline on budding and entry are estimated to have similar pharmacodynamics (PD), with entry effects estimated to have a slightly stronger response (lower C50 and higher Emax) compared with budding (Appendix Table S1). Based on PD parameters, the response to fendiline was estimated to be weaker in the BSL-4 assays, as is evident by higher C50 values and lower Emax values compared with the budding and entry assays (Appendix Table S1; Fig 8I). These PD parameter
Figure 7.
differences between budding and entry assays vs BSL-4 results could suggest that other parts of the viral life cycle not affected by fendiline (not quantified explicitly in these experiments) become rate limiting in the BSL-4 assays, thereby reducing the overall effect of fendiline on infection progression. In summary, a mathematical model consistent with three independent experimental systems, predicts a combination of budding and entry effects resulting in the observed BSL-4 effects, and estimates PD parameters for each mechanism.

Discussion

The host cell PM is exploited by filoviruses for their assembly and budding, where they can egress the host cell to form a new virion. The matrix protein, VP40, is the main driver of this process as it harbors a high affinity for lipids in the PM inner leaflet. Lipid binding by VP40, which includes selectivity for PS (Ruigrok et al., 2000; Scianimanico et al., 2000; Adu-Gyamfi et al., 2015; Del Vecchio et al., 2018) and PI(4,5)P2 (Johnson et al., 2016; preprint: Johnson et al.,
in vitro) drives and stabilizes, respectively, VP40 oligomers that are necessary for viral budding. In fact, VP40 has been shown to be sufficient (in the absence of other filovirus proteins) to form VLPs from the host cell PM that are nearly indistinguishable from virions (Jasenosky et al., 2001; Noda et al., 2002; Licata et al., 2003). Again, this underscores the unique properties of VP40 structure and sequence, which provides a template for host lipid binding, oligomerization, and sufficient information to encode cues for scission to complete the viral budding process. Further, VP40-derived VLPs enter cells in a PS-dependent manner, despite the absence of the EBOV glycoprotein (Jemiology et al., 2013). While some of the basic principles between VP40 and PM interactions have been previously revealed, the mechanistic consequences of the interactions and their potential pharmacological targeting have remained unknown.

In this study, we demonstrated that VP40 was able to cluster PS in the PM of cells. VP40-dependent PS clustering required PS binding and efficient PM localization of VP40, as the K224A-VP40 mutant, previously defined as a PS-binding residue did not significantly increase PS clustering. VP40 oligomerization was also crucial to PS clustering efficiency as a VP40 oligomerization-deficient mutant, which can still exhibit PM localization, significantly reduced PS clustering. This is an important point as the PM of host cells is generally thought to harbor 20–30 mol% PS in the inner leaflet. In fact, VP40 effectively binds and oligomerizes on PS-containing membranes with compositions close to the PS content of the PM inner leaflet. This is consistent with a recent computational study that demonstrated higher PS levels resulted in a higher VLP budding rate (Liu et al., 2022). In contrast, PS concentrations below 15 mol% did not provide robust affinity and oligomerization compared with those with 22 mol% PS and greater. PS clustering and PS content may also play a critical role in the loss of asymmetry that occurs during the EBOV budding process. For instance, pooling of PS in distinct regions of VP40 assembly may provide a cue for scramblases shown to distribute PS to the outer leaflet of the PM during the viral budding process (Nanbo et al., 2010; Younan et al., 2018; Acciani et al., 2021).

A recent study demonstrated that silencing PSS1, an enzyme responsible for PS synthesis in mammalian cells was sufficient to inhibit EBOV replication (Younan et al., 2018). However, to the best of our knowledge, small molecules aimed at targeting host cell lipid distribution have not previously been tested against EBOV. Fendiline was a logical choice to form an initial hypothesis of an FDA-approved drug that could inhibit EBOV budding as it was recently shown to lower PM PS (Choo et al., 2015) and inhibit K-Ras signaling (van der Hoeven et al., 2013, 2018) suggesting this FDA-approved drug may be sufficient to inhibit EBOV budding. Indeed, in BSL-4 experiments, fendiline was able to inhibit EBOV replication > 75% at 20 μM when given every day post-infection. Follow up mechanistic studies demonstrated that fendiline efficacy was due to inhibition of VP40 oligomerization, viral budding and viral entry. Thus, fendiline, which reduced the PS content of HEK293 cells by ~ 30% subsequently reduced PS clustering and VP40 oligomerization necessary for efficient viral budding. VLPs that did form from fendiline-treated cells had an overall reduced length and surface area, which likely combined with the reduced PS-content of the virus or VLPs to limit subsequent viral entry. Thus, disruption of PM PS content by one small molecule was sufficient to effect at least three important steps in the filovirus life cycle. Importantly, an increase in intracellular calcium due to fendiline can be ruled out in reducing and/or inhibiting EBOV and VP40 budding as calcium has been shown to be a critical component of VLP formation and virus replication (Han et al., 2015). Thus, an increase of calcium in HEK293 cells would be expected to increase and not decrease budding as we have observed.

Overall, this study lends credence to the hypothesis that host processes may be targeted to inhibit viral replication and spread. While the potency of fendiline may be low, the combination of fendiline with other FDA-approved drugs that have shown efficacy against EBOV (Johansen et al., 2013, 2015; Nelson et al., 2016; Dyall et al., 2018; Jasenosky et al., 2019) hold further promise. Fendiline was effective at 5 μM for reducing PS content in cells and the relationship to fendiline concentrations used in vitro is an important point to address in the future. Fendiline has been used in both single (200–1,200 mg) and multiple doses (400 mg, twice) per day, which was followed with pharmacokinetic evaluation yielding maximal plasma levels in patients of 9–170 ng/ml (Weynenmeyer et al., 1987). At the upper range of fendiline detected in the plasma, 170 ng/ml = 540 nM fendiline. Thus, at the upper value of fendiline detected from oral dosing, the concentration was lower than the 5 μM used to lower cellular PS. Part of the issue in fendiline dosing is rapid metabolism with a bioavailability of ~ 20% depending on the mg dose given (Kurovetz et al., 1982). Thus, the issue is not necessarily fendiline toxicity and efficacy but drug metabolism of fendiline in the plasma and through the hepatic 1st pass effect that limit plasma concentration available (Kurovetz et al., 1982). Thus, future studies geared towards more stable drugs that can alter PS content through a similar mechanism of action (via ASM inhibition) may be beneficial.

Recently, fendiline analogs have been generated that have nanomolar potencies against K-Ras PS-dependent PM localization and were effective at inhibiting cancer cell proliferation in the low micromolar range (Wang et al., 2021). Fendiline has also recently been shown to block SARS-CoV-2 S-mediated fusion (Xiao et al., 2020) and cause Leishmania infantum death via mitochondrial depolarization (Reimão et al., 2016). Thus, our work and these studies lay a framework to improved pharmacological targeting strategies against either VP40 matrix assembly or PS clustering that would not only reduce viral budding and spread but also lower subsequent viral entry, which partially relies on PS in the viral envelope (Jemiology et al., 2013; Moller-Tank et al., 2013; Moller-Tank & Maury, 2014; Brunton et al., 2019). Notwithstanding pharmacological principles learned from this study, a critical balance between VP40 and PS has been resolved demonstrating a critical need for VP40 clustering in the assembly and budding process. VP40 oligomers are needed for enhanced PS clustering where PS clustering seems to ensure optimal VP40 oligomerization.

Materials and Methods

Reagents and solutions

PBS, DMEM, ionomycin and Lipofectamine™ LTX with Plus™ Reagent, and Invitrogen™ Molecular Probes™ Hoechst 3342 were purchased from Fisher Scientific; heat-inactivated fetal bovine serum (FBS) was purchased from Hyclone, and Minimum Essential Medium (MEM) was purchased from Corning. Invitrogen Live Cell
Imaging Solution, Dil Stain, Halt™ Protease Inhibitor Cocktail, Pierce BCA Assay kit, and BS3 were purchased from ThermoFisher Scientific. Non-essential amino acids (NEAA) were purchased from Sigma Aldrich and L-glutamine was purchased from Gibco. Alexa Fluor™ 488 C2 Maleimide (Alexa-488) for protein conjugation was purchased from Invitrogen. Fendiline was purchased from Cayman Chemical.

Described previously (Adu-Gyamfi et al., 2012; Johnson et al., 2016). GFP-K224A-eVP40 was prepared by site directed mutagenesis (preprint: Johnson et al., 2018) and GFP-mVP40 was used as described previously (Wijesinghe & Stahelin, 2015; Amiar et al., 2021). The GFP-LactC2 plasmid was a kind gift from Sergio Grinstein (University of Toronto). GFP-PLC6PH was a kind gift from Tamas Balla (NIH). pCAG-GPI-GFP was a gift from Anna Katerina Hadjantonakis (Addgene #32601). pEGFP-N3-Annexin A2 was a gift from Volker Gerke & Ursula Rescher (Addgene #10796). pCAGGS-FLAG-eVP40 (NR49337) and pcDNA3.1-eGP (NR-19814) were obtained from BI Services. pCAGGS-TIM-1 was from Heinz Feldmann (Watt et al., 2014).

Plasmids

EGFP, EGFP-eVP40, and EGFP-WE/A-eVP40 were prepared as described previously (Adu-Gyamfi et al., 2012; Johnson et al., 2016). GFP-K224A-eVP40 was prepared by site directed mutagenesis (preprint: Johnson et al., 2018) and GFP-mVP40 was used as described previously (Wijesinghe & Stahelin, 2015; Amiar et al., 2021). The GFP-LactC2 plasmid was a kind gift from Sergio Grinstein (University of Toronto). GFP-PLC6PH was a kind gift from Tamas Balla (NIH). pCAG-GPI-GFP was a gift from Anna Katerina Hadjantonakis (Addgene #32601). pEGFP-N3-Annexin A2 was a gift from Volker Gerke & Ursula Rescher (Addgene #10796). pCAGGS-FLAG-eVP40 (NR49337) and pcDNA3.1-eGP (NR-19814) were obtained from BI Services. pCAGGS-TIM-1 was from Heinz Feldmann (Watt et al., 2014).

Lipids and LUV preparation

POPC (#850457), DPPC (#850355), Chol (#700000), DPPS (#840037), POPE (#850757), POP5 (#840034), Brain PI(4,5)P2 (#840046), and TopFluor® TMR-PS (#810242) were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL) and stored in chloroform and/or methanol at −20°C until use. For large unilamellar vesicle (LUV) preparation used in SPR and chemical crosslinking experiments, lipid mixtures were prepared at the indicated compositions (using a POPC matrix as the background and control and the indicated additions of PS at the expense of POPC), dried down to lipid films under a continuous stream of N2, and stored at −20°C until further use. On each day of experiments, LUVs were brought to room temperature, hydrated in either SPR buffer (10 mM HEPES, 150 mM NaCl, pH 7.4) or chemical crosslinking buffer (260 μM Raffinose pentahydrate in PBS, pH 7.4), vortexed vigorously, and extruded through a 100 nm (SPR experiments) or 200 nm (chemical crosslinking experiments) filter. Vesicle size was confirmed by dynamic light scattering using a DelsaNano S Particle Analyzer (Beckman Coulter, Brea, CA).

Preparation and imaging of GUVs

GUVs were prepared by a gentle hydration method (Reeves & Dowben, 1969; Darszon et al., 1980; Yamashita et al., 2002). Briefly, 1 mM of lipid control mixture was made and contained 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), cholesterol (Chol), and fluorescent PS (TopFluor® TMR-PS) at 90:9.8:0.2% molar ratio. For PS clustering and eVP40-binding analysis, 1,2-dipalmitoyl-sn-glycero-3-phosphoserine (DPPS) alone or with brain phosphatidylinositol 4,5-bisphosphate P1(4,5)P2 were added at 40 and 2.5% molar ratios, respectively, and the ratios of DPPC were adjusted accordingly. The lipid mixtures were prepared in 5 mL round-bottom glass flasks and the chloroform was removed with rotary movements under a continuous stream of N2 and even heat at 55°C until complete evaporation of the solvent. The lipid films were then hydrated overnight at 50°C (DPPC:Chol:TopFluor TMR-PS) and 55°C (DPPC:Chol:P1(4,5)P2:TopFluor TMR-PS) in an appropriate volume of GUV hydration buffer (150 mM NaCl, 10 mM HEPES, 0.5 M sucrose, pH 7.4).

For imaging, the freshly hydrated GUVs were diluted 10 times in GUV dilution buffer (150 mM NaCl, 10 mM HEPES, 0.5 M glucose, pH 7.4) and placed on a 6-mm diameter chamber made from a silicon sheet using a core sampling tool (EMS # 69039–60). The silicon chamber was mounted on a 1.5-mm clean coverglass (EMS # 72200–31) precoated with 1 mg/ml BSA. The set up was then assembled in an Attolflou chamber (Invitrogen # A7816) and 1.25 μM eVP40-Alexa488 was added. GUVs imaged for eVP40 and PS colocalization and clustering analysis was performed at 37°C on a Nikon Eclipse Ti Confocal inverted microscope (Nikon Instruments, Japan), using a Plan Apochromat 60×1.4 numerical aperture oil objective and a 100X 1.45 numerical aperture objective, respectively. A 488 nm argon laser was used to excite GFP and a 561 nm argon laser was used to excite TopFluor® TMR-PS. The 3D reconstruction was performed using ImageJ. Mander’s correlational analysis was performed using the plugin JACoP (Boile & Cordélieres, 2006).

Cell culture, transfections, and pharmacological treatments

All BSL-2 studies were performed using HEK293 cells obtained from the American Type Culture Collection and cultured in DMEM supplemented with 10% FBS and 1% PS. Transient transfections were performed using Lipofectamine™ PLUS™ Reagent, according to the manufacturer’s protocol. All transfections were performed in DMEM supplemented with 10% FBS. Treatment with fendiline (in DMSO) occurred at 5-h post-transfection in DMEM supplemented with 10% FBS. BSL-4 assays were also performed using Vero E6 cells cultured in MEM, 5% heat-inactivated fetal bovine serum, 1% L-glutamine, and 1% NEAA. Both HEK293 and Vero E6 cells were cultured and incubated at 37°C, 5% CO2, 80% humidity.

Biosafety

Experiments with authentic virus (Fig 4), were performed in dedicated BSL-4 facilities at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). This work was performed under a USAMRIID-approved safety protocol (AP-16-001). USAMRIID biological safety measures can be found in more detail here: https://usamriid.health.mil/biosafety/index.htm. The virus strain used was Ebola virus Kikwit. This work performed in BSL-4 uses the highest containment practices including the use of positive pressure suits by lab personnel and breathing of filtered air. Laboratory oversight is monitored by a number of federal agencies and third-party inspectors that have access to the Institute. A complete list of these agencies and inspectors can be found at the link above.

© 2022 The Authors
Immunoblotting

Samples prepared for western blotting analysis were first separated using SDS-PAGE (8% for chemical crosslinking and 12% for cell lysates and VLPs). Following transfer onto a nitrocellulose membrane, membranes were blocked with 5% MILK-TBST and analyzed with their respective antibodies (see Appendix Table S2). Antibodies were detected using an ECL detection reagent and imaged on the ImageQuant LAS 4000 or Amersham Imager 600 (GE Healthcare Life Sciences). All quantitative analysis derived from western blotting was performed using densitometry analysis in ImageJ.

Protein purification and Alexa-488 C₅ Maleimide labeling

The His₅₉-eVP40-pET46 expression vector was a kind gift from Dr. Erica Ollmann Saphire (La Jolla Institute for Immunology) and was expressed and grown in Rosetta™ 2 BL21 DE3 competent cells (Merck Millipore, Billerica, MA). The pet28a-His₅₉-Lact C2 bacterial expression plasmid was a kind gift from Dr. Sergio Grinstein. His₅₉-eVP40 and His₅₉-LactC2 were grown and purified as described previously (Johnson et al., 2016). Following elution from a Ni-NTA slurry (Qiagen), the protein samples were then further purified using size exclusion chromatography on a HiLoad 16/600 Superdex 200 pg column (ÅKTA pure, GE Healthcare). The desired fractions containing dimeric VP40 or monomeric LactC2 were collected, concentrated, and stored in 10 mM Tris, 300 mM NaCl, pH 8.0. Protein concentration was calculated using the Pierce BCA assay and the concentration was calculated using the Moments analysis thresholding (Tsai, 1985) was applied. To isolate the PM area, a default threshold was applied. To isolate PS clusters, the Moments analysis thresholding (Tsai, 1985) was applied. Following the moments analysis thresholding, the custom ImageJ macro was applied: despeckle, close-, fill holes, and remove outliers (radius = 5, threshold = 50). The sum of the remaining particles area was calculated, as well as the PM area. %PS clustering was calculated according to the ratio (Areaclusters/Areaplasma membrane).

Plasma membrane localization confocal microscopy

Live cell imaging experiments were performed at 24 and 48 h post treatment. Experiments to quantify fluorescent protein PM localization were performed on a Zeiss LSM 710 inverted microscope using a Plan Apochromat 63×1.4 numerical aperture oil objective. A 488 nm argon laser was used to excite GFP/EGFP. GFP-LactC2 PM localization was quantified ratiometrically by comparing the PM signal vs. the cytosolic signal. GFP-EOBV-VP40 and GFP-MARY-VP40 PM localization was quantified ratiometrically by comparing the PM signal vs. the total fluorescence signal within the cell.

TMR-PS quenching experiment

The TopFluor® TMR quenching analysis was performed as described previously (Zhao et al., 2010). Briefly, LUVs with 0.5% TopFluor® TMR-PS and increasing amounts of DPMS (0, 1, 5, 10, 20, 40, 60%) with or without PI(4,5)P₂ (2.5% with 60% DPMS) were made as described above. LUVs were then mixed at a final concentration of 40 μM with corresponding concentrations of eVP40 dimer in 10 mM HEPES, 160 mM NaCl pH 7.4 in a black/clear bottom 96-well plate and incubated at 37°C for 30 min. The TopFluor® TMR was excited at 547 nm and the fluorescence was recorded from 555 to 600 nm with no cutoff wavelength using the plate reader SpectraMax M5e (Molecular Devices, St Jose, CA). The fluorescence quenching ratio, ΔF, was calculated according to the ratio (F₀/F), where F₀ is the fluorescence in absence of protein and F is the fluorescence at a given eVP40 concentration.

Cellular Top Fluor TMR-PS clustering confocal microscopy

Each experimental day, a 100 μM working stock of TopFluor® TMR-PS in methanol was prepared. Immediately prior to imaging, cells were placed in 4°C for 5 min. The working stock was diluted to a final 500 nM TopFluor® TMR-PS solution in 3 mg/ml BSA/PBS. The 500 nM TopFluor® TMR-PS/BSA/PBS solution was incubated with cells at 4°C for 10 min, rinsed three times with cold PBS, and immediately imaged in fresh cold PBS. TopFluor® TMR was excited at 560 nm and GFP was excited at 488 nm. For PS clustering analysis, a custom macro in ImageJ was used. Prior to the macro analysis, background was subtracted, and the contrast was enhanced. To isolate the PM area, a default threshold was applied. To isolate PS clusters, the Moments analysis thresholding (Tsai, 1985) was applied. Following the moments analysis thresholding, the custom ImageJ macro was applied: despeckle, close-, fill holes, and remove outliers (radius = 5, threshold = 50). The sum of the remaining particles area was calculated, as well as the PM area. %PS clustering was calculated according to the ratio (Areaclusters/Areaplasma membrane).

Number and brightness

N&B experiments were performed as described previously (Adugyanfi et al., 2015; Bobone et al., 2017; preprint: Johnson et al., 2018; Amiar et al., 2021) on a Zeiss LSM 880 upright microscope using a LD “C-Apochromat” 40x/1.1 W Corr M27 objective. HEK293 cells expressing either GFP, GFP-LactC2 or GFP-eVP40 were treated with fendiline (1 or 5 μM) for 48-h prior to N&B analysis. Cells were imaged in phenol-free live cell imaging solution. For each experimental day, the brightness value of a monomer was determined in cells expressing monomeric GFP. Each image was acquired using the same laser power (0.01), resolution (256x256), pixel dwell time (16 us), frames (50), and zoom (pixel size of 50 nm). SimFCS Globals Software (Laboratory for Fluorescence Dynamics, University of California, Irvine, CA) was used for analysis.

Chemical crosslinking

His₅₉-eVP40 and His₅₉-LactC2 were purified as previously described in Protein purification and Alexa-488 C₅ Maleimide labelling. LUVs containing POPC and Brain P(4,5)P₂ (2.5%) with varying PS mol% composition (0, 15, 30, 60%) were prepared as previously described in Lipids and LUV preparation. Experimental protocol was adapted from (Johnson et al., 2016), and the manufacturers protocol for BS® (ThermoFisher) with each step performed at RT. In brief, protein (final concentration of 0.3 μM in PBS pH 7.4) was mixed with LUVs (final concentration = 660 μM) at a 1:1 volumetric ratio for 30 min.
Protein bound LUVs were separated from unbound protein through centrifugation (75,000 g, 30 min, 22°C), and resuspended in PBS (pH 7.4) buffer containing BSA (final concentration of 200 μM). Samples were incubated for 45 min, quenched with glycine for 15 min and then analyzed through western blotting. Following immunoblotting, oligomerization of VP40 was quantified ratiometrically by comparing VP40o vs. VP40m+d (where VP40o is the oligomeric VP40 band density (> 75 kDa) and VP40m+d is the sum of monomeric and dimeric eVP40 (~ 37 and 74 kDa) band density).

**Surface plasmon resonance**

To determine the affinity of His6-eVP40 to LUVs with increasing PS concentrations, SPR was performed. SPR experiments were performed at 25°C using a Biacore X100 as described previously (Adu-Gyamfi et al., 2015). In brief, an L1 chip was coated at 5 μl/min with LUVs containing 0% PS (100% POPC, PS added at the expense of POPC) on flow cell 1 and either 1%, 11%, or 22 mol% POPS on flow cell 2 (LUV preparation described in previous section, Lipids and LUV preparation). The LUV conjugated chip was stabilized by washing with 50 mM NaOH and blocked with 0.1 mg/ml BSA (in SPR buffer) at a flow rate of 10 μl/min until the response on each flow cell was < 100 response units (RU). For quantitative affinity analysis, each concentration of eVP40 was injected for 540 s at a flow rate of 10 μl/min with a 180 s delay, and the difference in response between flow cell 1 and flow cell 2 was recorded (ΔRU). The apparent Kd of vesicle binding was determined using the nonlinear least squares analysis: 

$$R_{eq} = R_{max} / (1 + [i]/K_d)$$

where $R_{eq}$ (measured in RU) is plotted against protein concentration (C). $R_{max}$ is the theoretical maximum RU response and $K_d$ is the apparent membrane affinity. Data were fit using the Kaleidagraph fit parameter of $(m_0+m_1)/(m_0 + m_2)$; m1 = 1, 100; m2 = 1. ΔRU data were normalized in GraphPad Prism 8 for windows (La Jolla, CA) and plotted in Kaleidagraph (Reading, PA).

**Lipidomics**

HEK293 cells were treated with the indicated concentration of fendiline for 48 h, collected through centrifugation, rinsed with PBS and protein concentration was determined. Cells were pelleted, flash frozen in liquid N2 and stored at −80°C until subsequent LC/MS/MS processing by Avanti Polar Lipids, Inc. Prior to LC−MS/MS analysis, lipids were extracted using the Folch method (Folch et al., 1957). The bottom chromolipid layer taken after centrifugation was diluted with internal standards for LPA, LPS, PA, and PS for quantitation by injection on LC−MS/MS. Samples were injected on a LC−MS/MS method using a Waters Acquity UPLC/AB Sciex 5500 MS system performing reversed phase separation of LPA and LPS and PA and PS components with MS/MS detection. Each molecular species identified by the [M+H] m/z of its acyl carbon:double bond (CC:DB i.e. 34:2 PA) was quantified against the response of the internal standards of known concentration. Content of individual and total LPA/PA and LPS/PS was reported. Values were corrected to 1 × 10⁶ cells for all samples.

**BSL-4 immunofluorescence assay**

Vero E6 cells were seeded at 2×10⁴ cells/well in black 96-well poly-D-lysine-treated plates (Greiner Bio-One Cellcoatl®). Twenty-four hours prior to infection, fendiline was diluted in 0.5% DMSO and Vero E6 cell culture media at indicated concentrations and added to cells. An equivalent percentage of DMSO in culture media served as the vehicle control. Following pretreatment, compound was removed, and cells were incubated with Ebola virus (Kikwit) at a multiplicity of infection (MOI) of 0.1 or 1.0 in a BSL-4 located at USAMRIID. Following absorption for 1 h, virus inoculum was removed and cells were washed. Plates were divided into three post-infection treatment groups (day 0, every day-e.d., every other day-e.o.d.), and received either culture media or freshly prepared fendiline or vehicle control. Cells were then treated daily with freshly prepared compound or left to incubate based on their designated treatment group. At 48 h (MOI = 1.0), 72, or 96 h (MOI = 0.1) post infection, cells were washed with PBS and submerged in 10% neutral-buffered formalin for 24 h prior to removal from the BSL-4 laboratory. Formalin was removed and cells were washed with PBS. Cells were blocked with 3% BSA/PBS cell staining buffer (BioLegend) and incubated at 37°C for 2 h. Ebola virus GP-specific mAb KZ52, diluted in 3% BSA/PBS, were added to appropriate wells containing infected cells and incubated at room temperature for 2 h. Cells were washed three times with PBS prior to addition of goat anti-human or goat anti-mouse IgG-Alexa-488 secondary antibody. Following 1-h incubation with secondary antibody, cells were washed 3 times prior to counterstaining with Hoechst’s stain diluted in PBS. Cells were imaged and percent of virus infected cells calculated using the Operetta High Content Imaging System and Harmony® High Content Imaging and Analysis Software (PerkinElmer).

**VLP collections & functional budding assays**

HEK293 cells were transfected and treated with fendiline as described in the previous section, Cell culture, transfection & pharmacological treatments. Budding assays were performed as described previously (Johnson et al., 2016; Harty, 2018). In brief, VLP containing supernatants were harvested from cells and clarified through low speed centrifugation. Clarified VLPs were loaded onto a 20% sucrose cushion in STE buffer (10 mM TRIS, 100 mM NaCl, 1 mM EDTA, pH 7.6), isolated through ultracentrifugation, and resuspended in either 150 mM ammonium bicarbonate (functional budding assays), 2.5% glutaraldehyde in 0.1 M cacodylate buffer (TEM experiments), STE buffer (entry assays) or 0.1 M phosphate buffer for CD and thermal melting (PB; 0.02 M sodium phosphate monobasic, 0.08 M sodium phosphate dibasic, pH 7.4). VLP samples were stored at −80°C for functional budding assays, −20°C for entry assays or 4°C for TEM and CD analysis.

For functional budding assays, cell lysate samples were harvested and lysed on ice with RIPA buffer (150 mM NaCl, 5 mM EDTA pH = 8, 50 mM Tris pH 7.4, 1% Triton-X, 0.1% SDS, 0.5% deoxycholic acid) supplemented with Halt™ Protease Inhibitor Cocktail. Prior to separation on a 12% SDS-PAGE gel, cell lysate and VLP sample volume loading were normalized to sample protein content, determined by a BCA assay. Gels were transferred to a nitrocellulose membrane and immunoblotting was performed as described previously in the section, Immunoblotting. Following ECL detection, VP40 cell lysate (VP40o) expression was normalized to the respective GAPDH band density. The relative budding index was calculated according to the ratio of densityVP40/densityC+VLP (where...
density_{VLP} is the eVP40 VLP band density and density_{C+VLP} is the eVP40 cell lysate + VLP band density.

**Scanning electron microscopy**

HEK293 cells were transfected with FLAG-eVP40 and treated as described in the previous section. Cell culture, transfections & pharmacological treatments. Cells were scraped and collected through low-speed centrifugation at 48 h post transfection, and stored in primary fixative (2% glutaraldehyde, 2% paraformaldehyde in 0.1 M cacodylate buffer, pH 7.35) at 4°C until processing. During processing, samples were fixed to coverslips and post-stained with 1% osmium tetroxide in 0.1 M cacodylate buffer. Samples were extensively rinsed with water and dehydrated with a graded series of ethanol followed by drying in a Tousimis 931 Supercritical Autosamdri® device. Prior to imaging, samples were coated with 3 nm Iridium. A Field Emission Scanning Electron Microscope Magellan 400 (FEI) (Hillsboro, OR) was used to collect images, with assistance from Tatyana Orlova at the Notre Dame Integrated Imaging Facility.

**Transmission electron microscopy imaging**

Virus-like particles were purified as previously described in VLP collections & functional budding assays. Following ultracentrifugation, VLPs were resuspended in fixative (2.5% glutaraldehyde in 0.1 M cacodylate buffer). Purified VLPs were applied onto glow discharged carbon formvar grids and negatively stained using 4% uranyl acetate. Samples were imaged with a FEI Tecnai T12 electron microscope equipped with a tungsten source and operating at 80 kV. VLP length and diameter measurements were quantified using ImageJ software. For diameter analysis, eight different diameters were measured across random areas on each VLP, and the mean diameter was reported.

**Circular dichroism**

Virus-like particles were produced in the presence of DMSO or fendiline and purified as previously described in the VLP collections & functional budding assays section. PB buffer was added to a 10-mm path-length Spectrosil Far UV Quartz cuvette (Starna Cells CatID: 21-Q-10) and a background spectrum was collected and auto-subtracted from VLP samples. VLP samples were loaded into the 10-mm cuvette diluted in PB buffer to an approximate final protein concentration of 30 μg/ml. Circular dichroism spectra of VLP samples were collected between 200–280 nm at a 0.2 nm step size with 0.5 s time-per-point (with adaptive sampling) using a Chirascan spectrometer (Applied Photophysics, Leatherhead, UK). Absorbance spectra (Abs) and detector signal (hv) were collected simultaneously as controls. After collecting the CD spectra, a microtit bar was added to the cuvette and thermal melting was run from 20 to 93°C using a 0.5°C step ramping at 1.00°C/min with a tolerance of 0.20°C; simultaneously, spectra were collected at a single wavelength of 220 nm with a time-per-point of 24 s. Absorbance spectra (Abs) and detector signal (hv) were collected simultaneously as controls. At the end of thermal melting measurement collection, temperature set-points were replaced with temperatures measured by the sample handling unit. Data were converted from Chirascan filetype to CSV and then extracted into GraphPad PRISM 7. Using the first derivative of the circular dichroism spectral signal in respect to temperature, the maxima was taken as the melting point of the sample. Melting temperatures of the three replicates were averaged for the reported $T_m$.

**Dil entry assay**

Virus-like particles produced from HEK293 cells expressing FLAG-eVP40 and eGP were purified as previously described in the VLP collections & functional budding assays section. Dil entry assays were performed as described previously (Kuroda et al., 2015; Nanbo et al., 2018). In brief, following ultra-centrifugation VLPs were resuspended in STE buffer and further purified by filtering through a 0.22 μm filter. Protein content of VLP samples were normalized to 0.1 μg/ml using STE buffer. VLPs were labeled with DiI for 1 h at RT with gentle agitation (final Dil = 0.06 μM). Following incubation, labeled VLP samples were concentrated down to equal volumes, and brought up to volume in phenol-free MEM with 2% FBS and 4% BSA.

HEK293 cells were transfected with TIM-1 for 24 h prior to incubation with Dil-labeled VLPs and briefly rinsed with phenol-free MEM with 2% FBS and 4% BSA. Dil-VLPs were added to TIM-1 expressing HEK293 cells, spinoculated for 45 min at 4°C, and allowed to incubate for 1 h at 37°C. Plates were then rinsed with PBS, fixed with 4% paraformaldehyde in PBS, their nuclei stained with Hoechst 3342, and stored at 4°C until imaging. During image acquisition, z-stacks were acquired of 10–15 frames (1 μm steps).

**Toxicity analysis**

HEK293 and Vero E6 cell toxicity following fendiline treatment was tested at the indicated time points using the Cell Titer Glo Viability Assay (Promega, Madison WI) according to the manufacturer’s protocol. In brief, HEK293 cells were treated with the indicated concentration of fendiline or control for 24 or 48 h. Vero E6 cells were treated for 24 h, the drug was removed, and the cells were replenished with Vero E6 culture media, to mirror the corresponding ebolavirus and Marburgvirus infections at BSL-4. Following the 1-h mock infection, cells were washed with PBS and plates were divided into three treatment groups (day 0, e.d., e.o.d.), and cells received either culture media or freshly prepared fendiline or vehicle control and were then treated daily with freshly prepared compound or left to incubate based on their designated treatment group. At 48, 72, and 96 h following mock infection, and mirroring the post infection fixation time points, CellTiter-Glo® reagent was added to each well in accordance with the manufacturer’s instructions. Both HEK293 and Vero E6 toxicity assays luminescence readings were recorded using a SpectraMax® M5 (Molecular Devices®) plate reader.

**Mathematical model of in vitro experiments**

We implemented a system of ordinary differential equations (ODEs) to describe the dynamics of host target cells, infected cells and free virus in different combinations reflecting the in vitro experimental systems used here. These equations are similar to those used to simulate Ebola virus dynamics in earlier work (Nguyen et al., 2015; Martyushev et al., 2016).
\[
\frac{dT}{dt} = -\beta TV \\
\frac{dl}{dt} = \beta TV - \delta l \\
\frac{dV}{dt} = pl - cV
\]

where \( T \), \( l \), and \( V \) represent numbers of susceptible target host cells, infected cells, and free virions, respectively, and parameters are described in Appendix Table S1.

We modified appropriate parameters in equations 1–3 to represent the following experimental systems during calibration of the mathematical model:

- Viral budding assay (set \( \beta = 0 \), \( T(0) = 0 \), \( l(0) = 2.625 \times 10^5 \), \( V(0) = 0 \), vary \( \delta \), \( \chi \), \( p \)).
- Viral entry assay (set \( p = 0 \), \( T(0) = 6.3 \times 10^5 \), \( l(0) = 0 \), \( V(0) = 6.3 \times 10^5 \), vary \( \beta \), \( \delta \), \( \chi \)).
- BSL-4 Cellular infection assay (BSL4) (\( T(0) = 5 \times 10^4 \), \( l(0) = 0 \), \( V(0) = 5 \times 10^4 \), MOI 0.1, vary \( \beta \), \( \delta \), \( \chi \)).

Fendiline treatment effects are simulated using \( E_{\text{max}} \) dose-response curves:

\[
 f_X = E_{\text{max}} \frac{C^{H}}{C_{50}^{H} + C^{H}}
\]

where \( C \) is the concentration of fendiline, \( E_{\text{max}} \) is the maximum effect of fendiline, \( H \) is the hill constant for the dose-response curve, and \( C_{50} \) is the concentration with 50% of \( E_{\text{max}} \) efficacy. \( E_{\text{max}} \), \( C_{50} \), and \( H \) are fitted separately for fendiline effects on budding (\( f_{\text{budding}} \)) or entry (\( f_{\text{entry}} \)). Fendiline efficacy (\( f_X \)) is defined as a fraction, where \( f_X = 0 \) implies no effect and \( f_X = 1 \) implies 100% inhibition of \( X \) (\( X \) = budding or entry). Fendiline effects are integrated into equations (1–3) by multiplying \( \beta \) by (1–\( f_{\text{entry}} \)) and multiplying \( p \) by (1–\( f_{\text{budding}} \)). Fendiline concentrations are assumed to be constant over the observation periods based on low in vitro degradation rates of the drug. Daily treatment in the BSL-4 assays (e.d.) are simulated by removing all free virus particles from the equations at each dosing time.

We calibrated the model in two stages. First, we calibrated to the budding and entry assays. The uncoupling of budding and entry in these data allows us to define biologically feasible ranges for the effects of fendiline on budding and entry separately. Using these feasible ranges, we proceed to calibrate the full model to the BSL-4 data (day-1/0 and e.d.). Therefore, we allow the budding and entry assays to inform the BSL-4 simulations without imposing strict assumptions about the equivalency between the two systems. In this way, we progressively build complexity into the model accounting for fendiline effects on viral budding, entry, and infection progression.

Calibrating to budding and entry assays we restrict the value of \( P \) to be larger than 1 and \( c \) to be between 0 and 5. These assumptions are in line with previous estimates, and are necessary to qualitatively reproduce viral production observed, but not quantified, in the budding assays. Parameters are estimated using Matlab’s nonlinear least squares optimization algorithm. Parameter bounds and final values are defined in Appendix Table S1.

**Statistical testing**

All experiments were done in triplicate (unless otherwise noted and figure legends indicate the number of replicates). For analysis of eVLP diameter and length from TEM experiments, as well as total PA levels between control and 5 \( \mu \)M fendiline-treated cells, a two-tailed t-test was performed. For all experiments which contained > 2 experimental groups, a one-way ANOVA with Dunnett’s multiple comparisons was performed on raw data. Lastly, for N&B analysis, a two-way ANOVA with Dunnett’s multiple comparisons was performed.

**Data availability**

No data were deposited in a public database and any additional data from this paper can be requested from the authors.

**Acknowledgements**

These studies were supported by the NIH (AI081077) to R.V.S. and the Indiana CTSI to E.P. and R.V.S. (UL1TR001108). M.L.H. was partially supported by a NIH T32 fellowship (T32 GM075762), E.A.D. was supported by a NIH T32 fellowship (GM132024), and C.B.P. was supported by a NIH T32 fellowship (AI148103). We are grateful for lipidomic analysis by Avanti Polar Lipids, Inc., and for research support by Dr. Nathan Dissinger. The authors acknowledge the use of the facilities of the Bindley Bioscience Center, a core facility of the NIH-funded Indiana Clinical and Translational Sciences institute and the use of the Purdue Life Science Electron Microscopy facility.

**Author contributions**

Monica L Husby: Conceptualization; formal analysis; funding acquisition; investigation; methodology; writing – original draft; writing – review and editing. Souad Amiar: Formal analysis; investigation; writing – review and editing. Laura I Prugar: Formal analysis; investigation; methodology; writing – review and editing. Emily A David: Formal analysis; funding acquisition; methodology; writing – review and editing. Kathleen E Huie: Formal analysis; investigation; writing – review and editing. Jennifer M Brannan: Supervision; writing – review and editing. John M Dye: Supervision; writing – review and editing. Elsje Pienaar: Formal analysis; supervision; funding acquisition; investigation; methodology. Robert V Stahelin: Supervision; funding acquisition; writing – original draft; project administration; writing – review and editing.

**Disclosure and competing interests statement**

The authors declare that they have no conflict of interest.

**References**

Acciani MD, Mendoza MF, Havranek KE, Duncan AM, Iyer H, Linn OL, Brindley MA (2021) Ebola virus requires phosphatidylserine scrambling activity for efficient budding and optimal infectivity. J Virol 95: e0116521
Adu-Gyamfi E, Digman MA, Gratton E, Stahelin RV (2012) Investigation of Ebola VP40 assembly and oligomerization in live cells using number and brightness analysis. Biophys J 102: 2517–2525

Adu-Gyamfi E, Soni SP, Xue Y, Digman MA, Gratton E, Stahelin RV (2013) The Ebola virus matrix protein penetrates into the plasma membrane: a key step in viral protein (VP40) oligomerization and viral egress. J Biol Chem 288: 5779–5789

Adu-Gyamfi E, Johnson KA, Fraser ME, Scott JR, Jones KR, Digman MA, Gratton E, Tessler CR, Stahelin RV (2015) Host cell plasma membrane phosphatidylserine regulates the assembly and budding of Ebola virus. J Virol 89: 9440–9453

Amara A, Mercer J (2015) Viral apoptotic mimicry. Nat Rev Microbiol 13: 461–469

Amiar S, Stahelin RV (2020) The Ebola virus matrix protein VP40 hijacks the host plasma membrane to form virus envelope. J Lipid Res 61: 971

Amiar S, Husby ML, Wijesinghe KJ, Angel S, Bhattachar N, Gerstman BS, Chapagain PP, Li S, Stahelin RV (2021) Lipid-specific oligomerization of the Marburg virus protein VP40 is regulated by two distinct interfaces for viroen assembly. J Biol Chem 296: 100:796

Banadyga L, Dolan MA, Ebihara H (2016) Rodent-adapted filoviruses and the molecular basis of pathogenesis. J Mol Biol 428: 3449–3466

Bayer R, Mannhold R (1987) Fendiline: a review of its basic pharmacological and clinical properties. Pharmatherapeutica 5: 103–136

Bell RM, Ballas LM, Coleman RA (1980) Phosphatidylethanolamine receptor CD₂₀ binds dengue virus and clinical properties. Annu Rev Pharm 19: 336–368

Bolte S, Cordelières FP (2006) A guided tour into subcellular colloidalization analysis in light microscopy. J Microsc 224: 213–232

Bornholdt ZA, Noda T, Abelson DM, Kaiko Y, Liao H, Gc JB, Oda S, Gerstman BS, Saphire EO, Chapagain PP, Stahelin RV (2018) A cationic, C-terminal patch and structural rearrangements in Ebola virus matrix VP40 protein control its interactions with phosphatidylserine. J Biol Chem 293: 3335–3349

Diagman MA, Dalal R, Horwitz AF, Gratton E (2008) Mapping the number of molecules and brightness in the laser scanning microscope. Biophys J 94: 2320–2332

Dyall J, Nelson EA, DeWald LE, Cuha R, Hart BJ, Zhou H, Postnikova E, Logue J, Vargas WM, Gross R et al (2018) Identification of combinations of approved drugs with synergistic activity against ebola virus in cell cultures. J Infect Dis 218: 5672–5678

Faird GD, Schieber NL, Ariotti N, Murphy S, Kearschner L, Webb RI, Grinstein S, Parton RG (2011) High-resolution mapping reveals topologically distinct cellular pools of phosphatidylserine. J Cell Biol 194: 257–227

Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226: 497–509

Graul AI, Pina P, Tracy M, Sorbera L (2020) This year’s new drugs and biologics. Drugs Today 56: 47–103

Han Z, Madara JJ, Herbert A, Prugar LI, Ruthel G, Lu J, Liu Y, Liu W, Liu X, Worobel JE et al (2015) Calcium regulation of hemorrhagic fever virus budding: mechanistic implications for host-oriented therapeutic intervention. PLoS Pathog 11: e1005220

Harty RN (2018) Hemorrhagic fever virus budding studies. In Hemorrhagic fever viruses: methods and protocols, MS Salvato (ed), pp 209–215. New York, NY: Springer

Hirama T, Das R, Yang Y, Ferguson C, Won A, Yip CM, Kay JG, Grinstein S, Parton RG, Faird GD (2017) Phosphatidylserine dictates the assembly and dynamics of caveolae in the plasma membrane. J Biol Chem 292: 14292–14307

Hoenen T, Biedenkopf N, Zielecki F, Jung S, Groseth A, Feldmann H, Becker S (2010) Oligomerization of Ebola virus VP40 is essential for particle morphogenesis and regulation of viral transcription. J Virol 84: 7053–7063

van der Hoeven D, Cho K, Ma X, Chigruputi S, Parton RG, Hancock JF (2013) Fendiline inhibits K-Ras plasma membrane localization and blocks K-Ras signal transmission. Mol Cell Biol 33: 237–251

van der Hoeven D, Cho K, Zhou Y, Ma X, Chen W, Naji A, Montufar-Solis D, Zuo Y, Kovar SE, Levental I et al (2018) Sphingomyelin metabolism is a regulator of K-Ras function. Mol Cell Biol 38: e00373–17

Huang CC, Huang CJ, Cheng JS, Liu SI, Chen IS, Tsai JY, Chou CT, Tseng PL, Jan CR (2009) Fendiline-evoked [Ca²⁺]ᵢ rises and non-Ca²⁺-triggered cell death in human oral cancer cells. Hum Exp Toxicol 28: 41–48

Jan CR, Tseng CJ, Chen WC (2000) Fendiline increases [Ca²⁺]ᵢ in Madin Darby canine kidney (MDCK) cells by releasing internal Ca²⁺ followed by capacitative Ca²⁺ entry. Life Sci 66: 1053–1062

Jan CR, Lee KC, Chou KJ, Cheng JS, Wang JL, Lo YK, Chang HT, Tang KY, Yu CC, Huang JK (2001) Fendiline, an anti-anginal drug, increases intracellular Ca²⁺ in PC3 human prostate cancer cells. Cancer Chemother Pharmacol 48: 37–41

Jasenosky LD, Kawaoka Y (2004) Filovirus budding. Virus Res 106: 181–188

Jasenosky LD, Neumann G, Lukaševeić I, Kawaoka Y (2001) Ebola virus VP40-induced particle formation and association with the lipid bilayer. J Virol 75: 5205–5214
Jasenosky LD, Cadena C, Mire CE, Borisevich V, Haridas V, Ranjbar S, Nambu A, Bavana S, Soloveva V, Sadukhan S et al (2019) The FDA-approved oral drug nitazoxanide amplifies host antiviral responses and inhibits Ebola virus. *Science* 19: 1279–1290

Jemielity S, Wang JJ, Chan YK, Ahmed AA, Li W, Monahan S, Bu X, Farzan M, Freeman CJ, Umetsu DT et al (2013) TIM-family proteins promote infection of multiple enveloped viruses through virion-associated phosphatidylserine. *PLoS Pathog* 9: e1003232

Johansen LM, Brannan JM, Delos SE, Shoemaker CJ, Stossel A, Lear C, Hoffstrom BG, Evans Dewald L, Schomburg KL, Scully C et al (2013) FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection. *Sci Transl Med* 5: 190ra79

Johansen LM, DeWald LE, Shoemaker CJ, Hoffstrom BG, Lear-Rooney CM, Stossel A, Nelson E, Simmons JA, Greiner JM, Erhard J,聘 (2015) A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity. *Sci Transl Med* 7: 290ra89

Johnson KA, Taghon GF, Scott JL, Stahelin RV (2016) The Ebola Virus matrix protein, VP40, requires phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) for extensive oligomerization at the plasma membrane and viral egress. *Sci Rep* 6: 19125

Johnson KA, Budicini MR, Urata S, Gerstman BS, Chapagain PP, Li S, Stahelin RV (2018) PI(4,5)P2 binding sites in the ebola virus matrix protein modulate assembly and budding. *bioRxiv* https://doi.org/10.1101/341248 [PREPRINT]

Johnson KA, Bhattacharjee K, Budicini MR, LaBonita CM, Baker SCB, Gerstman BS, Chapagain PP, Stahelin RV (2021) Cysteine mutations in the Ebolavirus matrix protein VP40 promote Phosphatidylserine binding by increasing the flexibility of a lipid-binding loop. *Viruses* 13: 1375

Kay JC, Koivusalo M, Ma X, Wohland T, Grinstein S (2012) Phosphatidylserine dynamics in cellular membranes. *Mol Biol Cell* 23: 2198–2212

Kerr D, Tietjen GT, Gong Z, Tajkhoshid E, Adams EJ, Lee KYC (2018) Sensitivity of peripheral membrane proteins to the membrane context: a case study of phosphatidylserine and the TIM proteins. *Biochim Biophys Acta Mol Cell Biol* 1860: 2126–2133

Kondratowicz AS, Lennemann NJ, Sinn PL, Davey RA, Hunt CL, Moller-Tank S, Meyerholz DK, Rennert P, Mullins PF, Brindley M et al (2011) T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus. *Proc Natl Acad Sci U S A* 108: 8426–8431

Kuroda M, Fujioka D, Nanbo A, Marzi A, Noyori O, Kajihara M, Maruyama J, Matsuno K, Miyamoto H, Yoshida R et al (2015) Interaction between TIM-1 and NPC1 is important for cellular entry of Ebola virus. *J Virol* 89: 6481–6493

Kurovetz WR, Brunner F, Beubler E, Weyhenmeyer R, Lohaus R, Grob M, Mayer D (1982) Single dose pharmacokinetics of fendiline in guinea pigs. *Eur J Drug Metab Pharmacokinet* 7: 105–110

Licata JM, Simpson-Holley M, Wright NT, Han Z, Paragas J, Harty RN (2003) Overlapping Motifs (PTAP and PPEY) within the Ebola Virus VP40 protein function independently as late budding domains: involvement of host proteins TSG101 and VPS-4. *J Virol* 77: 1812–1819

Liu L (2014) Fields virology, 6th edition. Edited by David M. Knipe and Peter M. Howley. Philadelphia, PA, USA. Lippincott Williams & Wilkins, 2013. 2456 pp: $439.99 (hardback). *Clin Infect Dis* 59: 613–613

Liu X, Pappas Ej, Husby ML, Mota BB, Stahelin RV, Pienaar E (2022) Mechanisms of phosphatidylserine influence on viral production: a computational model of Ebola virus matrix protein assembly. *J Biol Chem* 298: 102025

Llorente A, Skotland T, Sylvan G, Kauhanen D, Rog T, Orlowski A, Vattulainen I, Ekroos K, Sandvig K (2013) Molecular lipidomics of exosomes released by PC-3 prostate cancer cells. *Biochim Biophys Acta* 1831: 1302–1309

Madara JJ, Han Z, Ruthel G, Freedman BD, Harty RN (2015) The multifunctional Ebola virus VP40 matrix protein is a promising therapeutic target. *Future Virol* 10: 537–546

Maekawa M, Fairn GD (2019) Complementary probes reveal that phosphatidylserine is required for the proper transbilayer distribution of cholesterol. *J Cell Sci* 128: 1422–1433

Maekawa M, Lee M, Wei K, Ridgway ND, Fairn GD (2016) Stauroporine decrease ORMDL proteins and enhance sphingomyelin synthesis resulting in depletion of plasmalemmal phosphatidylserine. *Sci Rep* 6: 35762

Martyushev A, Nakaoka S, Sato K, Noda T, Iwami S (2016) Modelling Ebola virus dynamics: implications for therapy. *Antiviral Res* 135: 62–73

Menke M, Gerke V, Steinem C (2005) Phosphatidylserine membrane domain clustering induced by annexin A2/s100a10 heterotetramer. *Biochemistry* 44: 15296–15303

Miller ME, Adhikary S, Kolokoltsov AA, Davey RA (2012) Ebolavirus requires acid sphingomyelinase activity and plasma membrane sphingomyelin for infection. *J Virol* 86: 7473–7483

Moe JB, Lambert RD, Lupton HW (1981) Plaque assay for Ebola virus. *J Clin Microbiol* 13: 791–793

Moller-Tank S, Maury W (2014) Phosphatidylserine receptors: enhancers of enveloped virus entry and infection. *Virology* 468–470: 565–580

Moller-Tank S, Kondratowicz AS, Davey RA, Rennert PD, Maury W (2013) Role of the phosphatidylserine receptor TIM-1 in enveloped-virus entry. *J Virol* 87: 8327–8341

Mühlberger E (2007) Filovirus replication and transcription. *Future Virol* 2: 205–215

Mullard A (2020) FDA approves antibody cocktail for Ebola virus. *Nat Rev Drug Discov* 19: 827

Nanbo A, Kawaoka Y (2019) Molecular mechanism of externalization of phosphatidylserine on the surface of Ebola virus particles. *DNA Cell Biol* 38: 115–120

Nanbo A, Imai M, Watanabe S, Noda T, Takahashi K, Neumann G, Halfmann P, Kawaoka Y (2010) Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner. *PLoS Pathog* 6: e1001121

Nanbo A, Maruyama J, Imai M, Ujje M, Fujioka Y, Nishide S, Takada A, Ohba Y, Kawaoka Y (2018) Ebola virus requires a host scramblase for externalization of phosphatidylserine on the surface of viral particles. *PLoS Pathog* 14: e1006848

Nelson EA, Barnes AB, Wiehle RD, Fontenot GK, Hoenen T, White JM (2016) Clomiphene and its isomers block Ebola virus particle entry and infection with similar potency: potential therapeutic implications. *Viruses* 8: 206

Nguyen VK, Binder SC, Boianelli A, Meyer-Hermann M, Hernandez-Vargas EA (2015) Ebola virus infection modeling and identifiability problems. *Front Microbiol* 6: 257

Noda T, Sagara H, Suzuki E, Takada A, Kida H, Kawaoka Y (2002) Ebola Virus VP40 drives the formation of virus-like filamentous particles along with gp. *J Virol* 76: 4855–4865

Oda S, Noda T, Wijesinghe KJ, Halfmann P, Borohlde ZA, Abelson DM, Armbust T, Kawaoka Y, Stahelin RV, Saphire EO (2015) Crystal structure of marburg virus VP40 reveals a broad, basic patch for matrix assembly and a requirement of the N-terminal domain for immunosuppression. *J Virol* 90: 1839–1848

Panchal RS, Ruthel G, Kenny TA, Mallstrom GH, Lane D, Badie SS, Li L, Bavari S, Aman MJ (2009) *In vivo* oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding. *Proc Natl Acad Sci U S A* 106: 15936–15941
Reeves JP, Dowben RM (1969) Formation and properties of thin-walled phospholipid vesicles. *J Cell Physiol* 73: 49–60
Reimão Q, Mesquita JT, Ferreira DD, Tempone AG (2016) Investigation of calcium channel blockers as antiprotozoal agents and their interference in the metabolism of Leishmania (L.) infantum. *Evid Based Complement Alternat Med* 2016: 1523691
Ruigrok RW, Schoenh G, Dessen A, Forest E, Volchkov V, Olzinski O, Klenk HD, Weissenhorn W (2000) Structural characterization and membrane binding properties of the matrix protein VP40 of Ebola virus. *J Mol Biol* 300: 103–112
Scianimanico S, Schoenh G, Timmins J, Ruigrok RH, Klenk HD, Weissenhorn W (2000) Membrane association induces a conformational change in the Ebola virus matrix protein. *EMBO J* 19: 6732–6741
Skotland T, Sandvig K (2019) The role of PS 18:0/18:1 in membrane function. *Nat Commun* 10: 2752
Soní SP, Stahelin RV (2014) The Ebola virus matrix protein VP40 selectively induces vesiculation from phosphatidylinerine-enriched membranes. *J Biol Chem* 289: 33590–33597
Stahelin RV (2014) Membrane binding and binding in Ebola VP40 assembly and egress. *Front Microbiol* 5: 300
Stahelin RV, Scott JL, Frick CT (2014) Cellular and molecular interactions of phosphoinositides and peripheral proteins. *Chem Phys Lipids* 182: 3–18
Tsai WH (1985) Moment-preserving thresholding: a new approach. *Comput Vis Graph Image Process* 29: 377–393
Van Meer G, Voelker DR, Feigenson GW (2008) Membrane lipids: where they are and how they behave. *Nat Rev Mol Cell Biol* 9: 112–124
Wan W, Clarke M, Norris MJ, Kolesnikova L, Koehler A, Bornholdt ZA, Becker S, Saphire EO, Briggs JA (2020) Ebola and Marburg virus matrix layers are locally ordered assemblies of VP40 dimers. *Elife* 9: e592225
Wang YE, Park A, Lake M, Pentecost M, Torres B, Yun TE, Wolf MC, Holbrook MR, Freiberg AN, Lee B (2010) Ubiquitin-regulated nuclear-cytoplasmic trafficking of the Nipah virus matrix protein is important for viral budding. *PLoS Pathog* 6: e1001186
Wang J, Qiao L, Hou Z, Luo G (2017) TIM-1 promotes hepatitis C virus cell attachment and infection. *J Virol* 91: e01583–16
Wang P, van der Hoeven D, Ye N, Chen H, Liu Z, Ma X, Montufar-Solis S, Rehl KM, Cho KJ, Thapa S et al (2021) Scaffold repurposing of fendiline: identification of potent KRAS plasma membrane localization inhibitors. *Eur J Med Chem* 217: 113381
Watt A, Mokoumabi F, Banangyna L, Groseth A, Callison J, Herwig A, Ebihara H, Feldmann H, Hoenen T (2014) A novel life cycle modeling system for Ebola virus shows a genome length-dependent role of VP24 in virus infectivity. *J Virol* 88: 10511–10524
Wen Y, Vogt VM, Feigenson GW (2018) Multivalent cation-bridged PI[(4,5)P2] clusters form at very low concentrations. *Biophys J* 114: 2630–2639
Weyhenmeyer R, Fenzi I, Apecechea M, Rehm KD, Dyde CJ, Johnson KJ, Friedel R (1987) Tolerance and pharmacokinetics of oral fendiline. *Arzneimittel-Forschung* 37: 58–62
Wijesinghe KJ, Stahelin V (2015) Investigation of the lipid binding properties of the marburg virus. *J Virol* 90: 3074–3085
Xiao X, Wang C, Chang D, Wang Y, Dong X, Jiao T, Zhao Z, Ren L, Dela Cruz CS, Sharma L et al (2020) Identification of potent and safe antiviral therapeutic candidates against SARS-CoV-2. *Front Immunol* 11: 586572
Yamashita Y, Oka M, Tanaka T, Yamazaki M (2002) A new method for the preparation of giant liposomes in high salt concentrations and growth of protein microcrystals in them. *Biochim Biophys Acta* 1561: 129–134
Yeung T, Gilbert CE, Shi J, Slivius J, Kapus A, Grinstein S (2008) Membrane phosphatidyserine regulates surface charge and protein localization. *Science* 319: 210–213
Younan P, Lampietro M, Santos RI, Ramanathan P, Popov VL, Bukreyev A (2018) Disruption of phosphatidyserine synthesis or trafficking reduces infectivity of Ebola virus. *J Infect Dis* 218: S475–S485
Zhao H, Hakala M, Lappalainen P (2010) ADF/cofilin binds phosphoinositides in a multivalent manner to act as a PI(2)−density sensor. *Biophys J* 98: 2327–2336

License: This is an open access article under the terms of the *Creative Commons Attribution-NonCommercial-NoDerivs* License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
**Expanded View Figures**

**Figure EV1.** Fluorescence profiles of PS and WT-eVP40 through confocal microscopy and plot profile analysis of fluorescently labeled GUVs and Alexa488-eVP40.

A Representative confocal images of fluorescently labeled (TopFluor® TMR-PS) GUVs with varying lipid compositions (red) following incubation with eVP40-Alexa88 (green). Colocalization between eVP40 and PS within GUVs was indicated by plot profile analyses of fluorescence signals between TopFluor® TMR-PS (red dotted line) and eVP40-Alexa488 (green solid line) performed at indicated open yellow lines in a and shown in (B–D).

B Plot profile analysis of eVP40-Alexa488 and control GUVs (DPPC:Cholesterol:0.2 mol% TopFluor® TMR-PS).

C Plot profile analysis of eVP40-Alexa488 and PS GUVs (DPPC:Cholesterol:0.2 mol% TopFluor® TMR-PS:DPPS). * indicates overlap in fluorescence signals.

D Plot profile analysis of eVP40-Alexa488 and PS + P(4,5)P2 GUVs (DPPC:Cholesterol:0.2 mol% TopFluor® TMR-PS:DPPS:P(4,5)P2).

E Protein enrichment analysis (eVP40-Alexa488) measured as the fluorescence of eVP40 (Alexa488 labeled) at the GUV membrane divided by total fluorescence.

**** P < 0.0001, n = 3 biological replicates.

Data information: DPPC, dipalmitoyl-phosphatidylcholine; DPPS, dipalmitoyl-phosphatidylserine; PS, phosphatidylserine.
Figure EV2. Fluorescence profiles of PS and GFP-WT-eVP40 in HEK293 cells through confocal microscopy.

A Representative confocal images from live cell imaging of HEK293 expressing various GFP-fused proteins (GFP; green) following supplementation with TopFluor® TMR-PS (red). Solid white lines indicate where plot profile analysis was performed; scale bar = 10 μm.

B, C Validation of ability to detect exogenously added fluorescently labeled PS within the inner leaflet of the plasma membrane of cells (B) Plot profile analysis of HEK293 cells expressing cytosolic GFP. (C) Plot profile analysis of HEK293 cells expressing the PS sensor GFP-LactC2.

D, E Investigation of functionally distinct eVP40 proteins ability to bind to fluorescently labeled PS within the inner leaflet of the plasma membrane in living cells. (D) Plot profile analysis of HEK293 cells expressing GFP-WT-eVP40. (E) Plot profile analysis of HEK293 cells expressing GFP-K224A-eVP40 (PS-binding residue mutant).

F Plot profile analysis of HEK293 cells expressing GFP-WEA-eVP40 (oligomerization-deficient mutant).

Data information: (B–F) TopFluor® TMR-PS fluorescence signal intensity (red dotted line) and GFP fluorescence signal intensity (green solid line).
Figure EV2.
Figure EV3. Validation of in vitro and cellular PS clustering experiments.

A Representative images of the step-wise image analysis workflow of quantifying PS clustering in living HEK293 cells expressing GFP-fused proteins using a custom ImageJ macro. Scale bar = 10 μm.

B Representative images from live cell imaging experiments of HEK293 cells expressing control GFP-fused proteins specific for the plasma membrane (GPI), and specific lipids, PS (LactC2) and PI(4,5)P2 (PLCδ-PH) following supplementation with TopFluor® TMR-PS (red, middle panel). Scale bar = 10 μm.
Figure EV4. Profile of fendiline toxicity and efficacy in BSL-2 models.

A CellTiter-Glo® viability results of HEK293 cells. HEK293 cells were treated with fendiline for 24 h (black line) and 48 h (blue line) and viability was assessed as a % viability of control. Values are reported as mean ± s.d. n = 3 biological replicates.

B PS saturation analysis from lipidomic analysis (LC/MS/MS) of total lipids extracted from HEK293 cells treated with the indicated concentration of fendiline (48 h). Values are normalized to DMSO control and are reported as mean ± s.d.; n = 3 biological replicates; A one-way ANOVA was performed with multiple comparisons compared with the control DMSO.

C PA level analysis from lipidomic analysis (LC/MS/MS) of total lipids extracted from HEK293 cells treated with 5 μM fendiline (48 h). Values are normalized to DMSO control and are reported as mean ± s.d.; n = 3 biological replicates; A two-tailed t-test was performed.

D, E Analysis of PS plasma membrane localization in response to 24 h fendiline treatment. (D) Representative confocal images from live cell imaging of HEK293 cells expressing GFP-LactC2 and treated with fendiline for 24 h; scale bars = 10 μm. (E) Effect of fendiline on PS plasma membrane localization was calculated by the ratio of GFP fluorescence at the (plasma membrane intensity/intracellular intensity). Values are normalized to DMSO control and are reported as mean ± s.d.; N = 15 cell per replicate, n = 3 biological replicates; A one-way ANOVA was performed with multiple comparisons compared with the DMSO control. **P = 0.0045; ***P = 0.0003.

F N&B analysis of HEK293 cells expressing the control GFP. Analysis was performed at 48 h post treatment (DMSO) to align with N&B analysis performed on experiments with HEK293 cells expressing GFP-LactC2 or GFP-eVP40 and treated with the control or fendiline. Left panel: Representative images from time-lapse (30 frames) of HEK293 expressing EGFP and treated with 5 μM fendiline for 48 h. Scale bar = 5 μm. Middle panel: Brightness and Intensity plots for representative image. Right panel: Selection map correlating each pixel in the representative image to an oligomerization state (b value) (red: monomer-hexamer, green: hexamer-12mer, blue: 12mer-20mer). x- and y-axis label indicate distance in the 256x256 image.

Data information: N&B: number & brightness analysis; PA: phosphatidic acid; PS: phosphatidylserine.
Figure EV4.
Figure EV5. Vero E6 toxicity and effect of fendiline on eVP40 plasma membrane localization at 24 h post treatment.

A CellTiter-Glo viability results of Vero cells. Cells were treated with control or fendiline for 48 h according to the BSL-4 infection model; d-1/0 (treatment 1 h after infection, black line), e.d (treatment every day, blue line) and e.o.d (treatment every other day, gray line) and viability was assessed as a % viability of control. Values are reported as mean ± s.d. for n = 3 biological replicates. *P < 0.02.

B, C Effect of fendiline on eVP40 PM localization in HEK293 cells after 24 h of treatment. (B) Representative confocal images from live cell imaging experiments of HEK293 cells expressing EGFP-WT-eVP40 after 48 h of fendiline treatment. Scale bars = 10 μm. (C) Effect of fendiline on eVP40 PM localization was quantified by the ratio of EGFP fluorescence intensity at the PM / total GFP fluorescence intensity (and normalized to DMSO control). N > 15 cells per biological replicate, n = 3 biological replicates. Values are reported as mean ± s.d. A one-way ANOVA with multiple comparisons was performed compared with the DMSO control.

Data information: d-1/0, treatment 1 h after infection; e.d., every day; PM, plasma membrane.
APPENDIX

Phosphatidylserine clustering by the Ebola virus matrix protein is a critical step in viral budding

| Table of Contents | Page Number |
|-------------------|-------------|
| Appendix Figure S1 | 2-3         |
| Thermal melting of eVLPs produced in the presence and absence of fendiline. |
| Appendix Figure S2 | 4           |
| Calibration results from the first and second phase of model development. |
| Appendix Table S1 | 5           |
| Mathematical model parameter descriptions and values. |
| Appendix Table S2 | 6           |
| Antibodies used in immunoblotting. |
Appendix Figure S1
Thermal melting of eVLPs produced in the presence and absence of fendiline. A Ebola virus-like particles (eVLPs) were produced in DMSO treated HEK293 cells expressing FLAG-eVP40 and eGP constructs which were then collected, purified, and melted while measuring the loss in polarized light absorption at 220 nm. B Prior to melting, the circular dichroism spectra of DMSO VLPs was measured alongside the absorbance and detector (hv) signals. C Ebola VLPs were produced in 5 µM fendiline treated HEK293 cells using the same FLAG-eVP40 and eGP constructs which were then collected, purified and melted while measuring the loss in polarized light absorption at 220 nm. D Prior to melting, the circular dichroism spectra of fendiline VLPs was measured alongside the absorbance and detector (hv) signals.
Appendix Figure S2

Calibration results from the first and second phase of model development. A-C First phase calibration results between experimental (black bars) and simulation (gray) data from budding (A-B) and entry (C) assays. D-E Second phase calibration results showing comparison between experimental and simulation data from cell viability assays. The mathematical model was simultaneously calibrated to this data and the data in Figure 8 in the main text.
### Appendix Table S1. Mathematical model parameter descriptions and values

| Symbol | Description                                      | Unit                    | Value from calibration to budding and entry assays | Ranges based on fits to budding and entry assays | Value from calibration to BSL4 data – using ranges defined by budding and entry assays |
|--------|--------------------------------------------------|-------------------------|---------------------------------------------------|-------------------------------------------------|----------------------------------------------------------------------------------|
| β      | Infection rate constant of target cells by free virions | (Virion.day)^{-1}       | N/A                                               | 0 - inf                                         | 6.6x10^{-6}                                                                      |
| δ      | Death rate constant of infected cells            | Day^{-1}                | N/A                                               | 0 - inf                                         | 4.6x10^{-6}                                                                      |
| c      | Decay rate constant of free virions              | Day^{-1}                | N/A                                               | 0 - 5                                           | 5                                                                                |
| p      | Viral production rate constant by infected cells | Virions.(Infected cell.day)^{-1} | N/A                                               | 1 - inf                                         | 49                                                                               |
| $H_b$  | Hill constant for Fendiline effects on VLP budding |                         | 2.7                                               | 0.5 - 7                                         | 3.4                                                                               |
| $H_e$  | Hill constant for Fendiline effects on VLP entry  |                         | 11                                                | 0.5 - 20                                        | 4.7                                                                               |
| $C_{50}^b$ | Concentration with 50% of maximum Fendiline effect on VLP budding | µM                     | 5.7                                               | 2 - 20                                          | 18                                                                               |
| $C_{50}^e$ | Concentration with 50% of maximum Fendiline effect on VLP entry | µM                     | 4.8                                               | 0.5 - 20                                        | 15                                                                               |
| $E_{max}^b$ | Maximum Fendiline effect on VLP entry            |                         | 0.98                                              | 0.3 - 1                                         | 0.3                                                                               |
| $E_{max}^e$ | Maximum Fendiline effect on VLP entry            |                         | 0.76                                              | 0.3 - 1                                         | 0.33                                                              |
## Appendix Table S2. Antibodies used in immunoblotting.

| Target             | Species | Tag   | Dilution | Cat. #   | Source        |
|--------------------|---------|-------|----------|----------|---------------|
| eVP40              | Rabbit  |       | 1/40,000 | 0301-010 | IBT Bioservices |
| Rabbit             | Goat    | HRP   | 1/5,000  | 205718   | Abcam         |
| GAPDH              | Mouse   |       | 1/5,000  | 8245     | Abcam         |
| Mouse              | Sheep   | HRP   | 1/10,000 | 6808     | Abcam         |
| EBOV-GP (KZ52)     | Human   |       | 1.0 µg/ml| 0260-001 | IBT Bioservices |
| Human              | Goat    | Alexa-488 | 0.7 µg/ml| A11013   | Invitrogen    |
| Mouse              | Goat    | Alexa-488 | 1.0 µg/ml| A11029   | Invitrogen    |
| 6xHis              | Mouse   |       | 1/1,000  | A5588    | Sigma         |